<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological treatments for fatigue associated with palliative care - Mücke, M - 2015 | Cochrane Library</title> <meta content="Pharmacological treatments for fatigue associated with palliative care - Mücke, M - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006788.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological treatments for fatigue associated with palliative care - Mücke, M - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006788.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006788.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological treatments for fatigue associated with palliative care" name="citation_title"/> <meta content="Martin Mücke" name="citation_author"/> <meta content="martin.muecke@ukb.uni-bonn.de" name="citation_author_email"/> <meta content="mochamat Mochamat" name="citation_author"/> <meta content="Henning Cuhls" name="citation_author"/> <meta content="University Hospital of Bonn" name="citation_author_institution"/> <meta content="Vera Peuckmann-Post" name="citation_author"/> <meta content="Medical Faculty RWTH Aachen University" name="citation_author_institution"/> <meta content="Ollie Minton" name="citation_author"/> <meta content="St George's University of London" name="citation_author_institution"/> <meta content="Patrick Stone" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Lukas Radbruch" name="citation_author"/> <meta content="University Hospital of Bonn" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD006788.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/05/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006788.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006788.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006788.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amantadine [therapeutic use]; Benzhydryl Compounds [therapeutic use]; Carnitine [therapeutic use]; Central Nervous System Stimulants [therapeutic use]; Chronic Disease; Fatigue [*drug therapy, etiology]; Kidney Failure, Chronic [complications]; Methylphenidate [therapeutic use]; Modafinil; Multiple Sclerosis [complications]; Neoplasms [complications]; *Palliative Care; Pemoline [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006788.pub3&amp;doi=10.1002/14651858.CD006788.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006788\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006788\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","ru","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006788.pub3",title:"Pharmacological treatments for fatigue associated with palliative care",firstPublishedDate:"May 30, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006788.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006788.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006788.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006788.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006788.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006788.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006788.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006788.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006788.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006788.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7802 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006788.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-sec-0073"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-sec-0012"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-sec-0013"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-sec-0036"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-sec-0069"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/appendices#CD006788-sec-0078"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/supinfo/CD006788StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/supinfo/CD006788StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological treatments for fatigue associated with palliative care</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#CD006788-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Martin Mücke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#CD006788-cr-0005">mochamat Mochamat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#CD006788-cr-0006">Henning Cuhls</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#CD006788-cr-0007">Vera Peuckmann-Post</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#CD006788-cr-0008">Ollie Minton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#CD006788-cr-0009">Patrick Stone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information#CD006788-cr-0010">Lukas Radbruch</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information/en#CD006788-sec-0091">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 May 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006788.pub3">https://doi.org/10.1002/14651858.CD006788.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006788-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006788-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006788-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006788-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006788-abs-0001" lang="en"> <section id="CD006788-sec-0001"> <h3 class="title" id="CD006788-sec-0001">Background</h3> <p>This review updates the original review, 'Pharmacological treatments for fatigue associated with palliative care' and also incorporates the review 'Drug therapy for the management of cancer‐related fatigue'. </p> <p>In healthy individuals, fatigue is a protective response to physical or mental stress, often relieved by rest. By contrast, in palliative care patients' fatigue can be severely debilitating and is often not counteracted with rest, thereby impacting daily activity and quality of life. Fatigue frequently occurs in patients with advanced disease (e.g. cancer‐related fatigue) and modalities used to treat cancer can often contribute. Further complicating issues are the multidimensionality, subjective nature and lack of a consensus definition of fatigue. The pathophysiology is not fully understood and evidence‐based treatment approaches are needed. </p> </section> <section id="CD006788-sec-0002"> <h3 class="title" id="CD006788-sec-0002">Objectives</h3> <p>To evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases. </p> </section> <section id="CD006788-sec-0003"> <h3 class="title" id="CD006788-sec-0003">Search methods</h3> <p>For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PsycINFO and EMBASE, and a selection of cancer journals up to 28 April 2014. We searched the references of identified articles and contacted authors to obtain unreported data. To validate the search strategy we selected sentinel references. </p> </section> <section id="CD006788-sec-0004"> <h3 class="title" id="CD006788-sec-0004">Selection criteria</h3> <p>We considered randomised controlled trials (RCTs) concerning adult palliative care with a focus on pharmacological treatment of fatigue compared to placebo, application of two drugs, usual care or a non‐pharmacological intervention. The primary outcome had to be non‐specific fatigue (or related terms such as asthenia). We did not include studies on fatigue related to antineoplastic treatment (e.g. chemotherapy, radiotherapy, surgical intervention). We also included secondary outcomes that were assessed in fatigue‐related studies (e.g. exhaustion, tiredness). </p> </section> <section id="CD006788-sec-0005"> <h3 class="title" id="CD006788-sec-0005">Data collection and analysis</h3> <p>Two review authors (MM and MC) independently assessed trial quality and extracted data. We screened the search results and included studies if they met the selection criteria. If we identified two or more studies that investigated a specific drug with the same dose in a population with the same disease and using the same assessment instrument or scale, we conducted meta‐analysis. In addition, we compared the type of drug investigated in specific populations, as well as the frequent adverse effects of fatigue treatment, by creating overview tables. </p> </section> <section id="CD006788-sec-0006"> <h3 class="title" id="CD006788-sec-0006">Main results</h3> <p>For this update, we screened 1645 publications of which 45 met the inclusion criteria (20 additional studies to the previous reviews). In total, we analysed data from 18 drugs and 4696 participants. There was a very high degree of statistical and clinical heterogeneity in the trials and we discuss the reasons for this in the review. There were some sources of potential bias in the included studies, including a lack of description of the methods of blinding and allocation concealment, and the small size of the study populations. We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)‐associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta‐analysis. Treatment results pointed to weak and inconclusive evidence for the efficacy of amantadine, pemoline and modafinil in multiple sclerosis and for carnitine and donepezil in cancer‐related fatigue. Methylphenidate and pemoline seem to be effective in patients with HIV, but this is based only on one study per intervention, with only a moderate number of participants in each study. Meta‐analysis shows an estimated superior effect for methylphenidate in cancer‐related fatigue (standardised mean difference (SMD) 0.49, 95% confidence interval (CI) 0.15 to 0.83). Therapeutic effects could not be described for dexamphetamine, paroxetine or testosterone. There were a variety of results for the secondary outcomes in some studies. Most studies had low participant numbers and were heterogeneous. In general, adverse reactions were mild and had little or no impact. </p> </section> <section id="CD006788-sec-0007"> <h3 class="title" id="CD006788-sec-0007">Authors' conclusions</h3> <p>Based on limited evidence, we cannot recommend a specific drug for the treatment of fatigue in palliative care patients. Fatigue research in palliative care seems to focus on modafinil and methylphenidate, which may be beneficial for the treatment of fatigue associated with palliative care although further research about their efficacy is needed. Dexamethasone, methylprednisolone, acetylsalicylic acid, armodafinil, amantadine and L‐carnitine should be further examined. Consensus is needed regarding fatigue outcome parameters for clinical trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006788-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006788-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006788-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006788-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006788-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006788-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006788-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006788-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006788-abs-0002" lang="en"> <h3>Pharmacological treatments for fatigue associated with advanced disease </h3> <p>In an advanced disease such as cancer, fatigue can be described as tiredness, weakness or lack of energy. Fatigue can affect daily activity and quality of life, and it is frequently reported by palliative care patients. The underlying causes of fatigue are not very well understood and fatigue is difficult to treat. </p> <p>We searched the literature in April 2014 and found 45 randomised controlled trials for this update of the review. We analysed data from 4696 participants who received treatment for their fatigue. The trials dealt with neurological diseases (such as multiple sclerosis (753 participants), post‐polio syndrome (58) and Parkinson's disease (19)), different types of cancer (3223), HIV/AIDS (514), end‐stage renal disease (56), multi‐type advanced disease in hospice patients (30), amyotrophic lateral sclerosis (28) and end‐stage chronic lung disease (15). </p> <p>There was weak evidence for the efficacy of amantadine, pemoline and modafinil in reducing fatigue in patients with multiple sclerosis. There was also weak evidence for the efficacy of carnitine and donepezil for cancer‐related fatigue. One small trial showed that people with HIV/AIDS and fatigue seemed to benefit from treatment with methylphenidate or pemoline. There was some low‐quality evidence from small trials that methylphenidate, a stimulant drug that improves concentration, is effective for the management of cancer‐related fatigue. There was no information about dexamphetamine, paroxetine or testosterone. </p> <p>Previous studies have shown that erythropoietin and darbepoetin, drugs that improve anaemia (a shortage of red cells or haemoglobin in the blood), are also effective for cancer‐related fatigue. However, due to safety concerns and side effects shown by more recent studies, erythropoietin and darbepoetin should no longer be used. Therefore, we excluded these drugs from this review update. </p> <p>Overall, most side effects of the investigated drugs seemed to be mild.</p> <p>Based on limited evidence from small studies, the evidence does not support the use of a specific drug for the treatment of fatigue in palliative care. Future trials should measure fatigue in advanced disease using comparable and standardised measures. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006788-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006788-sec-0073"></div> <h3 class="title" id="CD006788-sec-0074">Implications for practice</h3> <section id="CD006788-sec-0074"> <p>This review update found no evidence to support the use of a specific drug to treat fatigue in palliative care patients. Amantadine seems to be promising in patients with multiple sclerosis and fatigue, while methylphenidate is advantageous in patients with cancer‐related fatigue. However, since the number of studies examining the effect of these drugs on fatigue, as well as the participant numbers, were relatively low, the evidence remains weak. Whether amantadine also relieves fatigue in cancer patients and whether methylphenidate relieves fatigue in multiple sclerosis patients has not been shown but should be investigated. Further studies are needed in patients with advanced disease and fatigue to show whether dexamethasone, methylprednisolone, donepezil, carnitine or modafinil may be beneficial, since the available evidence currently does not support these interventions. </p> <p>Overall, most adverse effects of the investigated drugs seemed to be fairly moderate. Patients with HIV/AIDS and fatigue should be offered treatment with methylphenidate or pemoline. Similarly, other drugs may be tested, if the above‐mentioned drugs are not available. </p> <p>Clinical practice includes corticosteroids as a short‐term therapeutic option for relief of fatigue in palliative care (<a href="./references#CD006788-bbs2-0132" title="RadbruchL , StrasserF , ElsnerF , GoncalvesJF , LogeJ , KaasaS , et al. Fatigue in palliative care patients -- an EAPC approach. Palliative Medicine2008;22(1):13-32. [PMID: 18216074]">Radbruch 2008</a>; <a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a>). However, only one randomised controlled trial (RCT) from our literature search matched the inclusion criteria (<a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a>). There are still not enough studies to show the therapeutic benefits of corticosteroids for this indication. </p> </section> <h3 class="title" id="CD006788-sec-0075">Implications for research</h3> <section id="CD006788-sec-0075"> <p><b>Patient group</b> </p> <p>Trials with a higher participant numbers may be able to detect small differences between groups. Palliative care studies in patients with advanced diseases, with the aim of relieving primary or secondary fatigue, should remain a focus of research. Further trials investigating subpopulations with different diseases in the end stage may be helpful. Stratification according to sociodemographic variables should be performed since, for example, younger age and male sex have been shown to predict worse fatigue (<a href="./references#CD006788-bbs2-0002" title="AuretKA , SchugSA , BremnerAP , BulsaraM . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. Journal of Pain and Symptom Management2009;37(4):613-21. [PMID: 18790598]">Auret 2009</a>; <a href="./references#CD006788-bbs2-0008" title="Butler JM Jr, CaseLD , AtkinsJ , FrizzellB , SandersG , GriffinP , et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics2007;69(5):1496-501. [PMID: 17869448]">Butler 2007</a>). </p> <p><b>Interventions</b> </p> <p>Amantadine, methylphenidate, carnitine, acetylsalicylic acid, dexamethasone, alfacalcidol, armodafinil and modafinil have been used in a few studies in this review with positive results. These drugs should be investigated in more detail to confirm their efficacy and should be examined for potentially similar efficacy in populations with different diseases and related fatigue. For instance, amantadine has been studied exclusively in multiple sclerosis patients and in post‐polio studies. Therefore, it may be relevant to examine the effect of amantadine in other populations, such as cancer patients. Also, investigation of corticosteroids in RCTs would be highly relevant. </p> <p><b>Comparisons</b> </p> <p>Future trials should compare one anti‐fatigue drug to another anti‐fatigue drug, combined with placebo‐controlled comparisons. </p> <p><b>Outcomes</b> </p> <p>There is no consensus on threshold values for relief of fatigue or on criteria for the responder. Patient‐reported fatigue and variance in the outcome instruments could be used to measure the improvement of fatigue. Outcomes should also clearly define both the response and adverse effects from the treatment. It would be helpful to agree on the use of particular measurement instruments in order to perform better comparisons and analysis (<a href="./references#CD006788-bbs2-0123" title="MintonO , StoneP . A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Annals of Oncology2009;20(1):17-25. [PMID: 18678767]">Minton 2009</a>). </p> <p><b>Trial design</b> </p> <p>Further research is needed to identify effective and safe treatment for fatigue in palliative care. Multi‐centre RCTs are recommended to assess the value of pharmacological treatments for fatigue. Additional data are required to confirm the results of this review and to provide a more significant estimate of efficacy. </p> <p>Overall, this review demonstrates a lack of evidence rather than a lack of efficacy of the interventions. With regard to future research, studies with larger participant numbers are needed. However, the difficulties of low recruitment and high attrition rates have been described repeatedly in research in palliative care, as patients with advanced and life‐threatening diseases are involved. It would also be helpful to limit the diversity of scales and scores used. Since no standardised recommendations for assessment of fatigue yet exist, it is difficult to determine whether the outcome measures were appropriate. Minton and Stone have suggested using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC‐QLQ‐C30) fatigue subscale or the Functional Assessment of Cancer Therapy fatigue scale (<a href="./references#CD006788-bbs2-0123" title="MintonO , StoneP . A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Annals of Oncology2009;20(1):17-25. [PMID: 18678767]">Minton 2009</a>). </p> <p>Interestingly, there were no more than two studies with a focus on corticosteroids and fatigue as the primary outcome (<a href="./references#CD006788-bbs2-0013" title="Della CunaGR , PellegriniA , PiazziM . Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. European Journal of Cancer and Clinical Oncology1989;25(12):1817-21. [PMID: 2698804]">Della Cuna 1989</a>; <a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a>), although corticosteroids have been recommended (<a href="./references#CD006788-bbs2-0108" title="RadbruchL , StrasserF , ElsnerF , GonçalvesJF , LøgeJ , KaasaS , et al, Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients -- an EAPC approach. Palliative Medicine2008;22:13-32. [DOI: 10.1177/0269216307085183] [PMID: 18216074]">EAPC 2008</a>) and are frequently used for this indication by clinicians since clinical experience shows a beneficial effect on many of the symptoms experienced by palliative care patients. The impact of corticosteroids should be investigated in future studies. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006788-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006788-sec-0008"></div> <p>This review is not only an update of a previously published review in the Cochrane Database of Systematic Reviews (<a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>). We have also conducted it with a new search strategy to incorporate another review on drug therapy for the management of cancer‐related fatigue (<a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a>), in order to increase its scope. </p> <p>In healthy individuals, fatigue serves as a protective response to physical or mental stress. By contrast, in patients with chronic disease, fatigue can be severely debilitating and thereby have an impact on quality of life and daily activities (<a href="./references#CD006788-bbs2-0126" title="MorrowGR , ShelkeAR , RoscoeJA , HickokJT , MustianK . Management of cancer-related fatigue. Cancer Investigations2005;23(3):229-39. [PMID: 15945509]">Morrow 2005</a>). Fatigue is a common symptom in palliative care patients and virtually every intervention used to treat cancer, as well as the primary disease itself, may cause or contribute to fatigue. In a study of 1000 patients in an American palliative care programme, fatigue, weakness and lack of energy were three of the five most frequently reported symptoms with a prevalence of 84%, 66% and 61%, respectively (<a href="./references#CD006788-bbs2-0146" title="WalshD , DonnellyS , RybickiL . The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Supportive Care in Cancer2000;8(3):175-9. [PMID: 10789956]">Walsh 2000</a>). Fatigue is also commonly reported in non‐cancer patients with progressive life‐threatening diseases, such as multiple sclerosis and amyotrophic lateral sclerosis (progressive degeneration of motor neurons leading to cumulative paralysis), as well as chronic heart, kidney or lung diseases (<a href="./references#CD006788-bbs2-0119" title="JhambM , LiangK , YabesJ , SteelJL , DewMA , ShahN , et al. Prevalence and correlates of fatigue in chronic kidney disease and end-stage renal disease: are sleep disorders a key to understanding fatigue?American Journal of Nephrology2013;38(6):489-95. [PMID: 24335380]">Jhamb 2013</a>; <a href="./references#CD006788-bbs2-0141" title="TangWR , YuCY , YehSJ . Fatigue and its related factors in patients with chronic heart failure. Journal of Clinical Nursing2010;19(1-2):69-78. [PMID: 20500245]">Tang 2010</a>). More than half of patients with multiple sclerosis describe fatigue as one of their most troubling symptoms (<a href="./references#CD006788-bbs2-0096" title="BakshiR . Fatigue associated with multiple sclerosis: diagnosis, impact and management. Multiple Sclerosis2003;9(3):219-27. [PMID: 12814166]">Bakshi 2003</a>; <a href="./references#CD006788-bbs2-0120" title="KruppLB . Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs2003;17(4):225-34. [PMID: 12665396]">Krupp 2003</a>; <a href="./references#CD006788-bbs2-0128" title="National Multiple Sclerosis Society. Management of MS-related fatigue. www.nationalmssociety.org/PRC.asp 2002 (accessed 17 November 2005).">NMSS 2002</a>). Fatigue has also been reported by the majority of patients with chronic obstructive pulmonary disease (COPD) (<a href="./references#CD006788-bbs2-0109" title="ElkingtonH , WhiteP , Addington-HallJ , HiggsR , EdmondsP . The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliative Medicine2005;19(6):485-91. [PMID: 16218161]">Elkington 2005</a>; <a href="./references#CD006788-bbs2-0140" title="StridsmanC , LindbergA , SkärL . Fatigue in chronic obstructive pulmonary disease: a qualitative study of people's experiences. Scandinavian Journal of Caring Sciences2014;28(1):130-8. [DOI: 10.1111/scs.12033] [PMID: 23517049]">Stridsman 2014</a>; <a href="./references#CD006788-bbs2-0144" title="TrendallJ . Assessing fatigue in patients with COPD. Professional Nurse2001;16(7):1217-20. [PMID: 12026780]">Trendall 2001</a>) and heart failure (<a href="./references#CD006788-bbs2-0117" title="GoodlinSJ . Palliative care for end-stage heart failure. Current Heart Failure Reports2005;2(3):155-60. [PMID: 16138952]">Goodlin 2005</a>). Approximately half of HIV patients suffer from fatigue (<a href="./references#CD006788-bbs2-0099" title="BreitbartW , McDonaldMV , RosenfeldB , MonkmanND , PassikS . Fatigue in ambulatory AIDS patients. Journal of Pain and Symptom Management1998;15(3):159-67. [PMID: 9564117]">Breitbart 1998</a>; <a href="./references#CD006788-bbs2-0129" title="NorvalDA . Symptoms and sites of pain experienced by AIDS patients. South African Medical Journal2004;94(6):450-4. [PMID: 15250459]">Norval 2004</a>). High levels of tumour necrosis factor (TNF) and interleukin‐1 from HIV infections may cause fatigue (<a href="./references#CD006788-bbs2-0106" title="DarkoDF , MitlerMM , HenriksenSJ . Lentiviral infection, immune response peptides and sleep. Advances in Neuroimmunology1995;5:57-77. [PMID: 7795894]">Darko 1995</a>). Cancer‐related fatigue is one of the most common symptoms experienced by cancer patients (<a href="./references#CD006788-bbs2-0105" title="CuhlsH , MückeM , MochamatM , RadbruchL . Underestimated symptom: frequent and burdensome than pain [Unterschätztes Symptom: Häufiger und belastender als Schmerzen]. Im Focus Onkologie2014;17(9):60-7. [DOI: 10.1007/s15015-014-0007-7]">Cuhls 2014</a>; <a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a>). It can be problematic at the time of diagnosis, during and after treatment and in patients with advanced disease (<a href="./references#CD006788-bbs2-0105" title="CuhlsH , MückeM , MochamatM , RadbruchL . Underestimated symptom: frequent and burdensome than pain [Unterschätztes Symptom: Häufiger und belastender als Schmerzen]. Im Focus Onkologie2014;17(9):60-7. [DOI: 10.1007/s15015-014-0007-7]">Cuhls 2014</a>; <a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a>). Most studies have reported prevalence figures in excess of 60% (<a href="./references#CD006788-bbs2-0139" title="StoneP . The measurement, causes and effective management of cancer-related fatigue. International Journal of Palliative Nursing2002;8(3):120-8. [PMID: 11923740]">Stone 2002</a>). The subjective sensations attributed to cancer‐related fatigue are characterised by a pervasive and persistent sense of tiredness, which is not relieved by sleep or rest. Several drugs, such as the new anti‐neoplastic therapies, may be associated with novel causes of secondary fatigue. Drugs regularly used in palliative care have sedative properties, for example opioid analgesics, benzodiazepines, antidepressants or anticonvulsants can cause fatigue load (<a href="./references#CD006788-bbs2-0108" title="RadbruchL , StrasserF , ElsnerF , GonçalvesJF , LøgeJ , KaasaS , et al, Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients -- an EAPC approach. Palliative Medicine2008;22:13-32. [DOI: 10.1177/0269216307085183] [PMID: 18216074]">EAPC 2008</a>). </p> <section id="CD006788-sec-0009"> <h3 class="title" id="CD006788-sec-0009">Description of the condition</h3> <p>The pathophysiology of fatigue in palliative care patients is not fully understood. 'Primary fatigue' has been said to be related to the high cytokine load (release of high amounts of cytokines from the tumour or antineoplastic therapy). Associated disease‐related symptoms, such as sleep disturbances, infections, malnutrition, hypothyroidism and anaemia, may also account for fatigue and may be termed 'secondary fatigue'. Synonyms for fatigue are asthenia, neuromuscular weakness and tiredness. There seems to be a considerable overlap between fatigue and depression. Weakness and tiredness are among the predominant symptoms of depression and feeling depressed is often part of the affective dimension of fatigue. However, there are some symptoms that are associated with depression (such as sustained feelings of worthlessness, recurrent thoughts of death) and some symptoms that are considered specific to fatigue (such as post‐exertional malaise). </p> <p>Different definitions have been proposed for fatigue. In partnership with the American Cancer Society, the National Comprehensive Cancer Network (NCCN) defines cancer‐related fatigue as "a distressing persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning" (<a href="./references#CD006788-bbs2-0127" title="National Comprehensive Cancer Network. Cancer related fatigue. www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf (accessed 30 October 2014).">NCCN 2014</a>). A similar definition has been used for multiple sclerosis: "a subjective lack of physical and/or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities" (<a href="./references#CD006788-bbs2-0128" title="National Multiple Sclerosis Society. Management of MS-related fatigue. www.nationalmssociety.org/PRC.asp 2002 (accessed 17 November 2005).">NMSS 2002</a>). The Fatigue Coalition has suggested the use of the International Classification of Diseases – 10 (ICD‐10) criteria for the definition of cancer‐related fatigue, which is "significant fatigue, diminished energy or an increased need to rest, disproportionate to any recent change in activity level" and has to be present every day or nearly every day for two consecutive weeks out of the last month (<a href="./references#CD006788-bbs2-0102" title="CellaD , DavisK , BreitbartW , CurtG . Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology2001;19(14):3385-91. [PMID: 11454886]">Cella 2001</a>). Five out of 10 additional symptoms, such as generalised weakness, diminished concentration or unrestorative sleep, are required for the diagnosis. However, the symptom thresholds and time span have been chosen arbitrarily (<a href="./references#CD006788-bbs2-0101" title="CellaD , PetermanA , PassikS , JacobsenP , BreitbartW . Progress towards guidelines for the management of fatigue. Oncology (Williston Park)1998;12(11A):369-77. [PMID: 10028520 ]">Cella 1998</a>), and this has been criticised. Considering the lack of an internationally acknowledged definition, we identified and chose the following working definition for this review: "Fatigue is a subjective feeling of tiredness, weakness, or lack of energy"; this definition has been suggested by an expert working group of the European Association of Palliative Care (<a href="./references#CD006788-bbs2-0108" title="RadbruchL , StrasserF , ElsnerF , GonçalvesJF , LøgeJ , KaasaS , et al, Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients -- an EAPC approach. Palliative Medicine2008;22:13-32. [DOI: 10.1177/0269216307085183] [PMID: 18216074]">EAPC 2008</a>). </p> </section> <section id="CD006788-sec-0010"> <h3 class="title" id="CD006788-sec-0010">Description of the intervention</h3> <p>Assessment of fatigue will depend on subjective self evaluation by the patient, substituted by caregiver or medical staff estimations only where self assessment is not possible. Single‐item scales (e.g. 'do you get tired for no reason?') have been proposed and a multitude of checklists and questionnaires with multiple dimensions (such as physical, affective and cognitive) have been validated (<a href="./references#CD006788-bbs2-0107" title="DittnerAJ , WesselySC , BrownRG . The assessment of fatigue: a practical guide for clinicians and researchers. Journal of Psychosomatic Research2004;56(2):157-70. [PMID: 15016573]">Dittner 2004</a>). </p> <p>Lack of consensus on the definition of fatigue and its subjective and multidimensional nature, as well as culture and language differences, have challenged research approaches to fatigue. Further, standard research studies, such as double‐blinded randomised controlled trials (RCTs), can often not be performed in this debilitated patient population due to fluctuating symptom intensity, declining performance status, rapid disease trajectories and short prognosis, resulting in weak evidence for treatment strategies. Several instruments exist to evaluate fatigue, but no consensus on significant cut‐off levels has yet been achieved to establish a model of clinically meaningful improvement of fatigue. Only a few scales and instruments have been evaluated for different languages (<a href="./references#CD006788-bbs2-0100" title="Cantarero-VillanuevaI , Fernández-LaoC , Díaz-RodríguezL , Cuesta-VargasAI , Fernández-de-las-PeñasC , PiperBF , et al. The Piper Fatigue Scale-Revised: translation and psychometric evaluation in Spanish-speaking breast cancer survivors. Quality of Life Research2014;23(1):271-6. [PMID: 23695719]">Cantarero‐Villanueva 2014</a>; <a href="./references#CD006788-bbs2-0121" title="KummerA , ScalzoP , CardosoF , TeixeiraAL . Evaluation of fatigue in Parkinson's disease using the Brazilian version of Parkinson's Fatigue Scale. Acta Neurologica Scandinavica2011;123(2):130-6. [DOI: 10.1111/j.1600-0404.2010.01364.x] [PMID: 20456242]">Kummer 2011</a>). A structured approach with assessment and treatment steps is lacking. As a result, fatigue continues to be underestimated and undertreated. Consequently, a structured approach, including treatment options, is needed. </p> <p>Treatment options for fatigue should address the causal mechanism if possible. However, the underlying mechanism of action is often not known and may be complex. Most patients will require symptomatic treatment of fatigue with pharmacological and non‐pharmacological therapies. Non‐pharmacological treatment options include patient education with provision of information on fatigue and its treatment, keeping a diary, energy expenditure planning and physical exercise (review in <a href="./references#CD006788-bbs2-0125" title="MockV . Evidence-based treatment for cancer-related fatigue. Journal of the National Cancer Institute. Monographs2004;32:112-8. [PMID: 15263051]">Mock 2004</a>; <a href="./references#CD006788-bbs2-0127" title="National Comprehensive Cancer Network. Cancer related fatigue. www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf (accessed 30 October 2014).">NCCN 2014</a>; <a href="./references#CD006788-bbs2-0137" title="SchmitzKH , HoltzmanJ , CourneyaKS , MasseLC , DuvalS , KaneR . Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers and Prevention2005;14(7):1588-95. [PMID: 16030088]">Schmitz 2005</a>). Recent studies support the use of resistance training or 'anabolic' exercise (<a href="./references#CD006788-bbs2-0114" title="GalvaoDA , NewtonRU . Review of exercise intervention studies in cancer patients. Journal of Clinical Oncology2005;23(4):899-909. [PMID: 15681536]">Galvao 2005</a>). Most patients will try to counteract exhaustion and fatigue with prolonged periods of rest (<a href="./references#CD006788-bbs2-0135" title="RichardsonA , ReamEK . Self-care behaviours initiated by chemotherapy patients in response to fatigue. International Journal of Nursing Studies1997;34(1):35-43. [PMID: 9055119]">Richardson 1997</a>). However, rest will often not restore energy and persistent reduction of physical activity may even promote fatigue (<a href="./references#CD006788-bbs2-0111" title="EvansWJ , LambertCP . Physiological basis of fatigue. American Journal of Physical Medicine and Rehabilitation2007;86:S29-46. [PMID: 17370370]">Evans 2007</a>). </p> <p>Pharmacological treatment of fatigue may work through interaction with cytokine load and the patient's host reaction to the underlying disease, restoring peripheral energy depletion, or by treating metabolic disorders and supplementing other apparent physiological deficiencies such as decreased haemoglobin concentration (<a href="./references#CD006788-bbs2-0126" title="MorrowGR , ShelkeAR , RoscoeJA , HickokJT , MustianK . Management of cancer-related fatigue. Cancer Investigations2005;23(3):229-39. [PMID: 15945509]">Morrow 2005</a>). There is a growing body of evidence that gives examples of effective pharmacological treatments for fatigue (<a href="./references#CD006788-bbs2-0003" title="BarakY , MagalashviliD , DolgopiatMD , LadkaniD , NitzaniD , MazorZ , et al. Effect of alfacalcidol on fatigue in ms patients: a randomized, double-blind study. Neurology2014;82(10 Suppl):S23.004. ">Barak 2014</a>; <a href="./references#CD006788-bbs2-0122" title="LawrenceDP , KupelnickB , MillerK , DevineD , LauJ . Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. Journal of the National Cancer Institute. Monographs2004;32:40-50. [PMID: 15263040]">Lawrence 2004</a>; <a href="./references#CD006788-bbs2-0126" title="MorrowGR , ShelkeAR , RoscoeJA , HickokJT , MustianK . Management of cancer-related fatigue. Cancer Investigations2005;23(3):229-39. [PMID: 15945509]">Morrow 2005</a>; <a href="./references#CD006788-bbs2-0130" title="PatrickDL , FerketichSL , FramePS , HarrisJJ , HendricksCB , LevinB , et al. National Institutes of Health state-of-the-science conference statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. Journal of the National Cancer Institute. Monographs2004;32:9-16. [PMID: 15263035]">Patrick 2004</a>; <a href="./references#CD006788-bbs2-0133" title="RaoA , CohenHJ . Symptom management in the elderly cancer patient: fatigue, pain, and depression. Journal of the National Cancer Institute. Monographs2004;32:150-7. [PMID: 15263059]">Rao 2004</a>; <a href="./references#CD006788-bbs2-0136" title="RosenbergJH , ShaforR . Fatigue in multiple sclerosis: a rational approach to evaluation and treatment. Current Neurology and Neuroscience Reports2005;5(2):140-6. [PMID: 15743552]">Rosenberg 2005</a>; <a href="./references#CD006788-bbs2-0145" title="WagnerLI , CellaD . Fatigue and cancer: causes, prevalence and treatment approaches. British Journal of Cancer2004;91(5):822-8. [PMID: 15238987]">Wagner 2004</a>; <a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a>; <a href="./references#CD006788-bbs2-0147" title="ZifkoUA . Management of fatigue in patients with multiple sclerosis. Drugs2004;64(12):1295-304. [PMID: 15200345]">Zifko 2004</a>). Drug treatment for non‐specific fatigue will be required by many patients in addition to specific measures against deficiencies or comorbid conditions. Concerning drug‐induced fatigue, for example with opioid treatment, symptomatic pharmacological treatment of fatigue may functionally counteract this adverse effect, probably by enhancing excitatory mechanisms as observed following treatment with amphetamines (<a href="./references#CD006788-bbs2-0138" title="SoodA , BartonDL , LoprinziCL . Use of methylphenidate in patients with cancer. American Journal of Hospice and Palliative Medicine2006;23:35-40. [PMID: 16450661]">Sood 2006</a>). </p> </section> <section id="CD006788-sec-0011"> <h3 class="title" id="CD006788-sec-0011">Why it is important to do this review</h3> <p>The latest systematic review about pharmacological treatments for fatigue associated with palliative care was published several years ago (<a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>). Other systematic reviews have covered the use of particular drugs for fatigue in multiple sclerosis, such as amantadine (<a href="./references#CD006788-bbs2-0131" title="PucciE , BranãsP , D'AmicoR , GiulianiG , SolariA , TausC , et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002818.pub2] [PMID: 17253480]">Pucci 2007</a>), and carnitine (<a href="./references#CD006788-bbs2-0142" title="TejaniAM , WasdellM , SpiwakR , RowellG , NathwaniS . Carnitine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD007280.pub3] [PMID: 22592719]">Tejani 2012</a>). Treatment of fatigue in cancer patients, including erythropoietic agents, was the subject of another Cochrane review with meta‐analysis (<a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a>). In contrast to this meta‐analysis our review aims to cover a broader scope of palliative care patients with cancer and non‐cancer diseases, but it is restricted to advanced‐stage diseases. We have incorporated the main topic of <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a> into this review, so that cancer‐related fatigue will be reflected. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006788-sec-0012" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006788-sec-0012"></div> <p>To evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006788-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006788-sec-0013"></div> <section id="CD006788-sec-0014"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006788-sec-0015"> <h4 class="title">Types of studies</h4> <p>We only included randomised controlled trials (RCTs). We considered full reports concerning fatigue in palliative care with a focus on pharmacological treatment. The primary outcome of these studies had to be fatigue (or related terms such as asthenia). We searched for diseases requiring palliative care or diseases at an advanced, life‐threatening stage. </p> </section> <section id="CD006788-sec-0016"> <h4 class="title">Types of participants</h4> <p> <ul id="CD006788-list-0001"> <li> <p>Age 18 years or more.</p> </li> <li> <p>Participants of both sexes.</p> </li> <li> <p>Palliative care patients with fatigue, i.e. patients with an incurable disease (terminal illness) such as advanced cancer, HIV/AIDS, multiple sclerosis, amyotrophic lateral sclerosis, or cardiac, lung or kidney failure. Participants could receive anticancer treatment. We considered terminal illness to be when the estimated life expectancy is six months or less, under the assumption that the disease will run its normal course. </p> </li> </ul> </p> </section> <section id="CD006788-sec-0017"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD006788-list-0002"> <li> <p>Identified studies had to evaluate and report the effect of pharmacological treatment on fatigue with the following drugs: psychostimulants (amphetamines, modafinil, armodafinil, methylphenidate, pemoline), amantadine, corticosteroids (dexamethasone, prednisone, methylprednisolone), donepezil, antidepressants such as selective serotonin reuptake inhibitors (SSRIs; paroxetine), acetylsalicylic acid, megestrol acetate, alfacalcidol and acetyl‐L‐carnitine. </p> </li> <li> <p>If we identified further agents used for the treatment of unspecific fatigue, we added these studies. </p> </li> <li> <p>Studies should compare fatigue with drug treatment versus no drug treatment or versus alternative drug treatment, or both. </p> </li> <li> <p>We did not include studies on the pharmacological treatment of fatigue with a primary target of clinical conditions such as depression or anxiety. </p> </li> <li> <p>We included antidepressants only if used for the treatment of fatigue as the primary outcome. </p> </li> <li> <p>We did not focus on physiological deficiencies such as lack of haemoglobin (erythropoietic agents, blood transfusion), nor did we focus on drugs targeting specific cytokines, e.g. for reduction of tumour necrosis factor alpha, as these treatments target specific aetiologies of fatigue. Erythropoietic agents have been covered in the review by Minton et al (<a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a>). </p> </li> <li> <p>We did not include studies comparing different types of cancer‐modifying treatment and the effect on prognosis and quality of life. We also excluded those studies which did not focus on pharmacological treatment. </p> </li> <li> <p>We did not include studies on fatigue related to antineoplastic treatment (e.g. chemotherapy, radiotherapy, surgical intervention). </p> </li> </ul> </p> </section> <section id="CD006788-sec-0018"> <h4 class="title">Types of outcome measures</h4> <section id="CD006788-sec-0019"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD006788-list-0003"> <li> <p>Patient‐reported fatigue (self reported measures or validated self assessment tools, or both), substituted by caregiver or medical staff estimations only where self assessment was not possible, and measurement using reliable and valid assessment instruments (single‐item scales or questionnaire instruments). </p> </li> <li> <p>Improvement of fatigue. Since no gold standard for the treatment or improvement of fatigue exists, we suggested an improvement of fatigue intensity by 33% related to the range of the assessment instrument to be clinically significant. This is congruent with the improvement of pain intensity, where a 33% reduction has been described as significant from the patient's point of view (<a href="./references#CD006788-bbs2-0112" title="FarrarJT , BerlinJA , StromBL . Clinically important changes in acute pain outcome measures: a validation study. Journal of Pain and Symptom Management2003;25(5):406-11. [PMID: 12727037]">Farrar 2003</a>). </p> </li> </ol> </p> </section> <section id="CD006788-sec-0020"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD006788-list-0004"> <li> <p>Asthenia (lack of strength) assessed with quality of life instruments such as SF‐36.</p> </li> <li> <p>Weakness assessed with scales, e.g. visual analogue scale ‐ fatigue (VAS‐F).</p> </li> <li> <p>Tiredness, sedation assessed with scales such as the Chalder Fatigue Scale (CFS) or Center for Epidemiologic Studies Depression (CESD) scale. </p> </li> <li> <p>Exhaustion, assessed with e.g. the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC‐QLQ‐C30). </p> </li> <li> <p>Treatment–related burden: adverse events (including cardiac arrhythmia and thromboembolic events), morbidity or mortality measured as percentages of participants, adverse events also measured as a percentage of participants with moderate/severe intensity, probability of a causal relationship between adverse events and treatment. </p> </li> </ol> </p> </section> </section> </section> <section id="CD006788-sec-0021"> <h3 class="title">Search methods for identification of studies</h3> <p>For this update, we have re‐engineered the search strategy (filter) of the previous review (<a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>) to facilitate the combination with another review (<a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a>). To identify studies for inclusion in this updated review, we developed a detailed search strategy for each electronic database and other resources. To validate the search strategy, we selected sentinel references. There were no language or date restrictions. </p> <section id="CD006788-sec-0022"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases:</p> <p> <ul id="CD006788-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 3); search strategy as detailed in <a href="./appendices#CD006788-sec-0079">Appendix 1</a>; </p> </li> <li> <p>MEDLINE (OVID) from inception to 28 April 2014; search strategy as detailed in <a href="./appendices#CD006788-sec-0080">Appendix 2</a>; </p> </li> <li> <p>EMBASE (OVID) from inception to 28 April 2014; search strategy as detailed in <a href="./appendices#CD006788-sec-0081">Appendix 3</a>; </p> </li> <li> <p>PsycINFO (OVID) from inception to 28 April 2014; search strategy as detailed in <a href="./appendices#CD006788-sec-0082">Appendix 4</a>. </p> </li> </ul> </p> </section> <section id="CD006788-sec-0023"> <h4 class="title">Searching other resources</h4> <p>We screened the reference lists of identified articles for additional studies.</p> <p>We handsearched standard textbooks on palliative medicine (<i>Oxford Textbook of Palliative Medicine</i> , Oxford; <i>Textbook of Nursing</i> , <i>Textbook of Palliative Medicine</i>). </p> <p>We also obtained unpublished literature through searches of conference proceedings, such as all meetings of the American Society of Clinical Oncology (ASCO) from 2000 to 2013, the 2013 meeting of the European Cancer Congress (ECCO) and the European Association of Palliative Care (EAPC) databases of all abstracts registered online from 2003 to 2014. </p> <p>We contacted experts in the field of fatigue in palliative care in order to identify research awaiting publication. </p> </section> </section> <section id="CD006788-sec-0024"> <h3 class="title" id="CD006788-sec-0024">Data collection and analysis</h3> <section id="CD006788-sec-0025"> <h4 class="title">Selection of studies</h4> <p>We retrieved in full all studies in which the abstract refers to drug intervention aimed at treating fatigue in palliative care. Eligible studies had to define fatigue as a primary outcome and at least one treatment arm had to be a drug intervention. </p> </section> <section id="CD006788-sec-0026"> <h4 class="title">Data extraction and management</h4> <p>We organised data using the software Review Manager 5.3 (<a href="./references#CD006788-bbs2-0134" title="Review Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). Two review authors extracted data (MM and MC) using a standard data extraction form. Two authors (MM and MC) reviewed the data from the included studies and two other authors (LR and HC) cross‐checked a sub‐sample. We resolved disagreement by consensus. </p> </section> <section id="CD006788-sec-0027"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (MM and MC) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006788-bbs2-0118" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane–handbook.org.">Higgins 2011</a>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion or by involving other review authors (LR, HC). We assessed the following for each study: </p> <p><b>Random sequence generation</b> (checking for possible selection bias) </p> <p>We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We carefully considered studies using a non‐random process. </p> <p><b>Allocation concealment</b> (checking for possible selection bias) </p> <p>The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (e.g. open list). </p> <p><b>Blinding of outcome assessment</b> (checking for possible detection bias) </p> <p>We assessed the methods used to blind study participants and outcome assessors from the knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, e.g. identical tablets, matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how this was achieved). We excluded studies that were not double‐blind. </p> <p><b>Incomplete outcome data</b> (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </p> <p>We assessed the methods used to deal with incomplete data as: low risk (less than 10% of participants did not complete the study and/or used 'baseline observation carried forward' analysis); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> <p><b>Size of study</b> (checking for possible biases confounded by small size) </p> <p>We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm). </p> </section> <section id="CD006788-sec-0028"> <h4 class="title">Measures of treatment effect</h4> <p>We intended to evaluate the methodological quality of each study, as well as the evidence for drug interventions to treat fatigue, using the GRADE system (<a href="./references#CD006788-bbs2-0095" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Atkins 2004</a>). We aimed to further evaluate studies by setting 'clinically relevant improvement' equal to improvement by one‐third compared to baseline fatigue intensity and to calculate a number needed to treat to benefit (NNTB) accordingly (NNTB to achieve at least a 33% improvement of fatigue intensity compared to the baseline fatigue level). We aimed to calculate numbers needed to treat to harm (NNTH) for adverse events with moderate or severe intensity. </p> <p>If calculation of the NNTB was not possible, 'clinically relevant improvement' would be defined as a change of 5% or more of the primary outcome instrument used in the study. This would be in accordance with the study of Cella et al, identifying changes between 3.7% and 5.8% of the aggregated summary scores as 'clinically important' (<a href="./references#CD006788-bbs2-0103" title="CellaD , EtonDT , LaiJ , PetermanSA , MerkelDE . Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management2002;24:547-61. [PMID: 12551804]">Cella 2002</a>). </p> <p>In addition, for each identified study, we aimed to extract:</p> <p> <ul id="CD006788-list-0006"> <li> <p>number of participants in each arm;</p> </li> <li> <p>type of control group;</p> </li> <li> <p>quality of the study (randomisation, blinding, per protocol analysis, intention‐to‐treat (ITT) analysis, number of withdrawals described); </p> </li> <li> <p>demographic characteristics, including age and sex;</p> </li> <li> <p>type of primary disease;</p> </li> <li> <p>type and stage of treatment, if applicable;</p> </li> <li> <p>type of drug used for the pharmacological intervention;</p> </li> <li> <p>duration and pharmacological regimen of drug treatment with the drug of interest;</p> </li> <li> <p>outcome measures employed, including means and standard deviations.</p> </li> </ul> </p> <p>We documented outcomes of fatigue in different ways. If we identified two or more studies that investigated a specific drug with the same dose in a population with the same disease and same assessment instrument or scale, we conducted a meta‐analysis. We aimed to calculate the standardised mean difference (SMD) in fatigue intensity, stating whether it had reached a potentially significant cut‐off level and we aimed to compare these data to other interventions and control groups, wherever available. Wherever appropriate, we calculated standard deviations (SD) for standardisation of the mean difference (MD) as the square root of the average of the variances before and after the intervention. Similarly, if only 95% confidence intervals (CI) were described, we converted these values to SDs by dividing the difference of the CI and mean by a factor of 1.96. </p> <p>A NNTB of 50% reduction has been suggested as significant for an exercise intervention in cancer‐related fatigue (<a href="./references#CD006788-bbs2-0104" title="CrampF , Byron-DanielJ . Exercise for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD006145.pub3] [PMID: 23152233]">Cramp 2012</a>). Since only limited information on the cut‐off level for clinically significant fatigue has been identified to date, we suggested a 33% improvement as a basis for NNTB calculation, since palliative care patients are more debilitated than the population that was examined in the <a href="./references#CD006788-bbs2-0104" title="CrampF , Byron-DanielJ . Exercise for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD006145.pub3] [PMID: 23152233]">Cramp 2012</a> review. A 33% reduction of pain intensity has been described as significant from the patients' point of view in studies on breakthrough pain management (<a href="./references#CD006788-bbs2-0112" title="FarrarJT , BerlinJA , StromBL . Clinically important changes in acute pain outcome measures: a validation study. Journal of Pain and Symptom Management2003;25(5):406-11. [PMID: 12727037]">Farrar 2003</a>). </p> </section> <section id="CD006788-sec-0029"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the individual patient.</p> </section> <section id="CD006788-sec-0030"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the original investigators to request missing data. We used intention‐to‐treat (ITT) analysis where possible. The ITT population consisted of participants who were randomised, took the assigned study medication and provided at least one post‐baseline assessment. We assigned missing participants zero improvement (baseline observation carried forward (BOCF), where this could be done. We were aware that imputation methods might be problematic and examined trial reports for information about them. </p> </section> <section id="CD006788-sec-0031"> <h4 class="title">Assessment of heterogeneity</h4> <p>We explored the homogeneity of the results of the various endpoints of interest using I² statistic values. We regarded heterogeneity in the results as a result of many potential factors (postulated a priori), and we made efforts to identify subgroups for sensitivity analysis. We undertook meta‐analysis. As a result of high statistical heterogeneity, we used a random‐effects model for analysis. If possible, and where applicable, we conducted subgroup analyses to explore possible sources of heterogeneity due to participants, interventions or methods. </p> <p>Potential sources of heterogeneity:</p> <p> <ul id="CD006788-list-0007"> <li> <p>disease entities;</p> </li> <li> <p>performance status;</p> </li> <li> <p>quality of studies;</p> </li> <li> <p>medication dose and frequency;</p> </li> <li> <p>duration of treatment;</p> </li> <li> <p>duration of follow‐up;</p> </li> <li> <p>rate of attrition;</p> </li> <li> <p>outcome measures used;</p> </li> <li> <p>case mix/stage of disease accessed.</p> </li> </ul> </p> </section> <section id="CD006788-sec-0032"> <h4 class="title">Assessment of reporting biases</h4> <p>To decrease the influence of potential publication bias, we conducted manual and electronic searches of multiple databases, without imposing any language restriction, to check for published or registered study protocols and to verify whether results from these studies have been published subsequently. We contacted the trial authors by email if there was insufficient information to assess reporting bias. We also contacted the authors to clarify information, if there were mismatches between study protocols and reports. </p> </section> <section id="CD006788-sec-0033"> <h4 class="title">Data synthesis</h4> <p>For data synthesis, we used Review Manager 5.3 (<a href="./references#CD006788-bbs2-0134" title="Review Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>), as provided by The Cochrane Collaboration. We grouped meta‐analyses of the data from all included studies using the I² statistic. If the I² value was greater than or equal to 50% (substantial or considerable heterogeneity), we used a random‐effects model. If the I² value was less than 50%, we used a fixed‐effect model. We reported the results from both models. </p> </section> <section id="CD006788-sec-0034"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to conduct a subgroup analysis where data were available. We performed separate analysis for different kinds of primary diseases (such as cancer or multiple sclerosis). If it was not possible to carry out a quantitative analysis, then we considered a qualitative review and a synthesis of the study results. </p> <p>In this review, we performed subgroup analyses for the following:</p> <p> <ul id="CD006788-list-0008"> <li> <p>different types of drug treatment;</p> </li> <li> <p>different types of disease;</p> </li> <li> <p>different types of assessment tools.</p> </li> </ul> </p> </section> <section id="CD006788-sec-0035"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analysis for the primary outcome measurements in order to explore effect size differences and the robustness of our conclusions. We planned sensitivity analysis determined a priori based on: </p> <p> <ul id="CD006788-list-0009"> <li> <p>studies without study limitations with regard to a) allocation concealment; b) blinding of participants and investigators; c) recruitment bias; d) baseline imbalance between groups; e) loss to follow‐up of clusters; f) adequate analysis; </p> </li> <li> <p>method of analysis: results of a) studies using number of patients analysed; b) studies using number of patients randomised. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006788-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006788-sec-0036"></div> <section id="CD006788-sec-0037"> <h3 class="title">Description of studies</h3> <p>This review updates and combines two existing reviews: <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a> and <a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>. The previous review, <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a>, found 31 studies involving 7140 participants and the review <a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a> identified 22 eligible studies with a total of 1632 participants. We used a new search strategy for this update, providing 1645 results that we screened. Most of these articles did not focus on fatigue as a primary outcome but on the drug treatment of underlying disease. The updated search strategy identified 20 additional studies suitable for inclusion. Only seven of the studies included in the <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a> review, but all 22 of the previously included studies in <a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>, matched our results. The small number of matched study results between this updated review and the <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a> review is due to the fact that we did not include haemopoietic growth factors in our search strategy. Safety concerns have been raised regarding the erythropoiesis‐stimulating agents (erythropoietin and darbepoetin) since the last publication of the original review, therefore the use of these drugs is no longer recommended in practice (<a href="./references#CD006788-bbs2-0097" title="BennettCL , SilverSM , DjulbegovicB , SamarasAT , BlauCA , GleasonKJ , et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA2008;299(8):914-24. [DOI: 10.1001/jama.299.8.914] [PMID: 18314434]">Bennet 2008</a>; <a href="./references#CD006788-bbs2-0098" title="BohliusJ , SchmidlinK , BrillantC , SchwarzerG , TrelleS , SeidenfeldJ , et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet2009;373(9674):1532-42. [DOI: 10.1016/S0140-6736(09)60502-X] [PMID: 19410717]">Bohlius 2009</a>; <a href="./references#CD006788-bbs2-0108" title="RadbruchL , StrasserF , ElsnerF , GonçalvesJF , LøgeJ , KaasaS , et al, Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients -- an EAPC approach. Palliative Medicine2008;22:13-32. [DOI: 10.1177/0269216307085183] [PMID: 18216074]">EAPC 2008</a>; <a href="./references#CD006788-bbs2-0115" title="GlaspyJA . Erythropoietin in cancer patients. Annual Review of Medicine2009;60:181-92. [DOI: 10.1146/annurev.med.60.050307.110718] [PMID: 18980468]">Glaspy 2009</a>; <a href="./references#CD006788-bbs2-0116" title="GlaspyJ , CrawfordJ , VansteenkisteJ , HenryD , RaoS , BowersP , et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. British Journal of Cancer2010;102:301-15. [DOI: 10.1038/sj.bjc.6605498] [PMID: 20051958]">Glaspy 2010</a>; <a href="./references#CD006788-bbs2-0143" title="TonelliM , HemmelgarnB , ReimanT , MannsB , ReaumeMN , LloydA , et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. Canadian Medical Association Journal2009;180(11):62-71. [DOI: 10.1503/cmaj.090470] [PMID: 19407261]">Tonelli 2009</a>). We found and removed 186 duplicate studies (<a href="#CD006788-fig-0001">Figure 1</a>). We checked the retrieved articles against the inclusion criteria and included 45 studies. We identified no additional unpublished data by contacting experts in palliative care and we retrieved no additional studies from the handsearched reference lists or abstract databases on the Internet. </p> <div class="figure" id="CD006788-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006788-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Meta‐analysis of data was possible for modafinil in multiple sclerosis (two studies, n = 136 participants), pemoline in multiple sclerosis (two studies, n = 103 participants) and methylphenidate in cancer patients (two studies, n = 146 participants). </p> <p>See also <a href="./references#CD006788-sec-0100" title="">Characteristics of included studies</a> and <a href="./references#CD006788-sec-0101" title="">Characteristics of excluded studies</a>. </p> <section id="CD006788-sec-0038"> <h4 class="title">Results of the search</h4> <p>We screened 1645 publications, of which 45 met the inclusion criteria and we included them for further analysis. In total, we analysed data from 18 drugs and 4696 participants. We used studies investigating pemoline and modafinil in participants with multiple sclerosis‐associated fatigue and methylphenidate in participants suffering from cancer and fatigue for meta‐analysis. </p> </section> <section id="CD006788-sec-0039"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD006788-sec-0100" title="">Characteristics of included studies</a> table. </p> <p>The 45 studies retrieved for the review yielded a broad spectrum of diseases associated with fatigue as well as different drugs (<a href="#CD006788-tbl-0001">Table 1</a>). </p> <div class="table" id="CD006788-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Drug treatment of fatigue: Populations, substances and outcome measures</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Patient population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Substance</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome measures</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue in advanced cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amphetamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI, McGill Quality of Life Questionnaire, ECOG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0002" title="AuretKA , SchugSA , BremnerAP , BulsaraM . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. Journal of Pain and Symptom Management2009;37(4):613-21. [PMID: 18790598]">Auret 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACT‐An, LASA, MMSE, KPS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0011" title="CrucianiRA , DvorkinE , HomelP , CullineyB , MalamudS , LapinJ , et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. Journal of Pain and Symptom Management2009;37(4):622-31. [PMID: 18809275]">Cruciani 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI, FACIT‐F, depression and pain instrument</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0012" title="CrucianiRA , ZhangJJ , ManolaJ , CellaD , AnsariB , FischMJ . L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology2012;30(31):3864-9. [PMID: 22987089]">Cruciani 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paroxetine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSC, MFI, Monopolar Profile of Mood States</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F, ESAS, daily diary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function, FACIT‐F, CESD, MMSE, KPS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0008" title="Butler JM Jr, CaseLD , AtkinsJ , FrizzellB , SandersG , GriffinP , et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics2007;69(5):1496-501. [PMID: 17869448]">Butler 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI, SED, SF‐36 vitality subscale, LASA, PSQI, SGIC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0032" title="RothAJ , NelsonC , RosenfeldB , ScherH , SlovinS , MorrisM , et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer2010;116(21):5102-10. [PMID: 20665492]">Roth 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0014" title="EscalanteCP , MeyersC , ReubenJM , WangX , QiaoW , ManzulloE , et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer Journal (Sudbury, Mass.)2014;20(1):8-14. [PMID: 24445757]">Escalante 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Donepezil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F, ESAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0007" title="BrueraE , El OstaB , ValeroV , DriverLC , PeiBL , ShenL , et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2007;25(23):3475-81. [PMID: 17687152]">Bruera 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NOSIE, LASA, Physician's Global</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0013" title="Della CunaGR , PellegriniA , PiazziM . Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. European Journal of Cancer and Clinical Oncology1989;25(12):1817-21. [PMID: 2698804]">Della Cuna 1989</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI, ESS, POMS‐DD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT, ESS, HADS, QOL‐LAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACT‐G</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0015" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungSH , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [PMID: 12743146]">Fisch 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standardised Mistletoe extract</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACT‐G</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0033" title="SemiglazovVF , StepulaVV , DudovA , SchnitkerJ , MengsU . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research2006;26(2B):1519-29. [PMID: 16619567]">Semiglazov 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medroxyprogesterone acetate (MPA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACT‐G</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0035" title="SimonsJP , AaronsonNK , VansteenkisteJF , ten VeldeGP , MullerMJ , DrenthBM , et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Journal of Clinical Oncology1996;14(4):1077-84. [PMID: 8648360]">Simons 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Megestrol acetate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC‐QLQ‐C30 instrument</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0043" title="WestmanG , BergmanB , AlbertssonM , KadarL , GustavssonG , ThaningL , et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer1999;35(4):586-95. [PMID: 10492632 ]">Westman 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue in amyotrophic lateral sclerosis (ALS)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGI‐E, FSS, ESS, BDI, RFS, VAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0028" title="RabkinJG , GordonPH , McElhineyM , RabkinR , ChewS , MitsumotoH . Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle and Nerve2009;39(3):297-303. [PMID: 19208404]">Rabkin 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue in HIV/AIDS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Armodafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGI‐I, FSS, HDRS, BDI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0030" title="RabkinJG , McElhineyMC , RabkinR . Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics2011;52(4):328-36. [PMID: 21777715]">Rabkin 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGI‐I, FSS, HDRS, BDI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amphetamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCID; HDRS, BFI, BHS, VAS for mood, CFS, VAS for energy level</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0041" title="WagnerGJ , RabkinR . Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2000;61(6):436-40. [PMID: 10901342]">Wagner 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGIS "was expanded to include ratings of energy, as well as mood and a global rating. Significant improvement was defined as score of 1 or 2 on CGIS"; HDRS, CFS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGIS ratings for libido, mood, energy and erectile function; CFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0026" title="RabkinJG , WagnerGJ , RabkinR . A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry2000;57(2):141-7; discussion 155-6. [PMID: 10665616]">Rabkin 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body composition, muscle strength and physical function, MOS‐30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0018" title="KnappPE , StorerTW , HerbstKL , SinghAB , DzekovC , DzekovJ , et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. American Journal of Physiology. Endocrinology and Metabolism2008;294(6):E1135-43. [PMID: 18430965]">Knapp 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body composition, muscle strength and physical function, MOS‐30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue in multiple sclerosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS‐F, KEDSS, mBDI; tolerance of adverse effects and checklist to identify their nature</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0042" title="WeinshenkerBG , PenmanM , BassB , EbersGC , RiceGP . A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology1992;42(8):1468-71. [PMID: 1641137]">Weinshenker 1992</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, MS Specific Fatigue Scale, subjective response (verbal rating)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, Fatigue Impact Scale, Beck Depression Inventory, Social Experience Checklist</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, Fatigue Impact Scale, Beck Depression Inventory, Social Experience Checklist</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS; mBDI, "Stroop Interference Test" (attentional measure of freedom from distracting information) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0010" title="CohenRA , FisherM . Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology1989;46(6):676-80. [PMID: 2730380]">Cohen 1989</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS; mBDI, "Stroop Interference Test" (attentional measure of freedom from distracting information) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0025" title="MurrayTJ . Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences1985;12(3):251-4. [PMID: 3902184]">Murray 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS, patient preference</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0031" title="RosenbergGA , AppenzellerO . Amantadine, fatigue, and multiple sclerosis. Archives of Neurology1988;45:1104-6. [PMID: 2972270]">Rosenberg 1988</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS; BDI; VAS‐F</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0009" title="Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Canadian Journal of Neurological Sciences1987;14(3):273-8. [PMID: 2889518]">Canadian MSRG 1987</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0001" title="AshtariF , FatehiF , ShaygannejadV , ChitsazA . Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?Neurologia i Neurochirurgia Polska2009;43(5):428-32. [PMID: 11176767]">Ashtari 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFIS, KEDSS, CESD, SGIC, FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, alertness test, NHPT, TMS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0021" title="LangeR , VolkmerM , HeesenC , LiepertJ . Modafinil effects in multiple sclerosis patients with fatigue. Journal of Neurology2009;256(4):645-50. [PMID: 19367356]">Lange 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFIS, VAS‐F, ESS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0037" title="StankoffB , WaubantE , ConfavreuxC , EdanG , DebouverieM , RumbachL , et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology2005;64(7):1139-43. [PMID: 15824337]">Stankoff 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, VAS‐F, FIS, SF‐36 QOL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0040" title="VasconcelosOM , ProkhorenkoOA , SalajeghehMK , KelleyKF , LivorneseK , OlsenCH , et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology2007;68(20):1680-6. [PMID: 17502549]">Vasconcelos 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FIS, QOL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfacalcidol (Vit. D)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FIS, QOL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0003" title="BarakY , MagalashviliD , DolgopiatMD , LadkaniD , NitzaniD , MazorZ , et al. Effect of alfacalcidol on fatigue in ms patients: a randomized, double-blind study. Neurology2014;82(10 Suppl):S23.004. ">Barak 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal</b> </p> <p><b>disease (ESRD)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KDQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0004" title="BrassEP , AdlerS , SietsemaKE , HiattWR , OrlandoAM , AmatoA , et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. American Journal of Kidney Diseases2001;37(5):1018-28. [PMID: 11325685]">Brass 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parkinson's disease</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFI, ESS, CESD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0022" title="LouJS , DimitrovaDM , ParkBS , JohnsonSC , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clinical Neuropharmacology2009;32(6):305-10. [PMID: 19620846 ]">Lou 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multi‐type advanced</b> </p> <p><b>disease (hospice</b> </p> <p><b>patients)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS, VAS‐F, ESAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0017" title="KerrCW , DrakeJ , MilchRA , BrazeauDA , SkretnyJA , BrazeauGA , et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. Journal of Pain and Symptom Management2012;43(1):68-77. [PMID: 20564068]">Kerr 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage COPD</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paroxetine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36, chronic respiratory questionnaire: 1 of 4 domains was fatigue, geriatric depression scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0020" title="LacasseY , BeaudoinL , RousseauL , MaltaisF . Randomized trial of paroxetine in end-stage COPD. Monaldi Archives for Chest Disease2004;61(3):140-7. [PMID: 15679006]">Lacasse 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postpolio syndrome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0038" title="SteinDP , DambrosiaJM , DalakasMC . A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Annals of the New York Academy of Sciences1995;753:296-302. [PMID: 7611638]">Stein 1995</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BDI = Beck Depression Inventory; BFI = Brief Fatigue Inventory; BHS = Beck Hopelessness Scale; CESD = Center for Epidemiologic Studies Depression; CFS = Chalder Fatigue Scale; DB = double‐blind; ECOG = performance status according to the Eastern Cooperative Oncology Group Scale; EORTC‐QLQ‐C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; ESAS = Edmonton Symptom Assessment System; ESS = Epworth Sleepiness Scale; FACIT‐F = Functional Assessment for Chronic Illness Therapy ‐ Fatigue; FACT‐An = Functional Assessment of Cancer Therapy ‐ Anaemia; FIS = Fatigue Impact Scale; FSC = Fatigue Symptom Checklist; FSS = Fatigue Severity Scale; HADS = Hospital Anxiety and Depression Scale; HDRS = Hamilton Depression Rating Scale; IM = intramuscular; ITT = intention‐to‐treat; IV = intravenous; KDQ = Kidney Disease Questionnaire; KEDSS = Kurtzke Expanded Disability Status Scale; KPS = Karnofsky Performance Status; LASA = Linear Analogue Scale Assessments; MAF = Multidimensional Assessment of Fatigue; mBDI = Modified Beck Depression Inventory; MFI = Multidimensional Fatigue Inventory; MMSE = Mini Mental State Examination; MOS‐30 = Medical Outcomes Study‐Short Form 30; MPMM = Monopolar Profile of Mood States; MS = multiple sclerosis; MS SFS = Multiple Sclerosis Specific Fatigue Scale; NHPT = Nine Hole Peg Test; NOSIE = Nurses' Observational Scale for Inpatient Evaluation; NRS = numeric rating scale; PC = placebo‐controlled; PFS = Piper Fatigue Scale; PO = per oral; POMS‐DD = Depression‐Dejection subscale of the Profile of Mood States; prn = as needed; PSQI = Pittsburgh Sleep Quality Index; pts = participants; QOL = RAYS quality of life; QOL‐LAS = quality of life linear analogue scale; RCT = randomised controlled trial; RFS = Role Function Scale; RT = radiation therapy; sc = subcutaneous; SCID = depression according to Structured Clinical Interview for DSM‐IV; SD = standard deviation; SE = standard error; SEC = Social Experience Checklist; SED = Symptom Experience Diary; SF‐36 = Short Form‐36; SGIC = Subject Global Impression of Change; TMS = transcranial magnetic Social Experience Checklist; VAS = visual analogue scale; VAS‐F = visual analogue scale ‐ fatigue </p> </div> </div> <p>Fatigue was typically examined in association with diseases as follows: multiple sclerosis (13 studies), HIV/AIDS (including HIV and hypogonadism) (seven studies), cancer (including advanced cancer, cancer of different origins and brain tumours) (18 studies), post‐polio (two studies), Parkinson's disease (one study), end‐stage renal disease (ESRD) (one study), amyotrophic lateral sclerosis (one study), multi‐type advanced disease (hospice patients) (one study) and end‐stage COPD (one study). </p> <p>Drug studied were as follows: amantadine (nine studies), pemoline (three studies), megestrol acetate (one study), methylphenidate (seven studies), dexamphetamine (two studies), paroxetine (two studies), acetyl‐L‐carnitine (four studies), testosterone (three studies), donepezil (one study), modafinil (eight studies), dexamethasone (one study), fluoxetine (two studies), alfacalcidol (one study), armodafinil (one study), mistletoe extract PS76A2 (one study), methylprednisolone (one study), medroxyprogesterone acetate (one study) and acetylsalicylic acid (two studies). </p> <p>In contrast, <a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a> examined fatigue related to both cancer and treatment. <a href="./references#CD006788-bbs2-0041" title="WagnerGJ , RabkinR . Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2000;61(6):436-40. [PMID: 10901342]">Wagner 2000</a> and <a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a> examined fatigue in patients with depression, where it may be difficult to differentiate whether fatigue was primary or secondary to depression. </p> <p>Most studies reported data from a relatively small number of participants: for the 45 studies included, only 17 reported a participant number greater than 100. Participant numbers, including controls, varied from six (<a href="./references#CD006788-bbs2-0031" title="RosenbergGA , AppenzellerO . Amantadine, fatigue, and multiple sclerosis. Archives of Neurology1988;45:1104-6. [PMID: 2972270]">Rosenberg 1988</a>) to 544 (<a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a>). The total number of participants who completed the studies included in our analysis was 4696. Issues associated with inconclusive findings were as follows: differences in data reporting, heterogenous populations, inconsistent symptom assessment (the use of instrument differed greatly) and lack of a consistent definition for a clinically significant reduction in fatigue. Therefore it was not possible to calculate the NNTB or NNTH, nor could we calculate a 5% reduction of fatigue as consistently as intended and described above. </p> <p>Some trials in this review only used single‐item fatigue assessment. However, it is now considered by European palliative care experts that a single‐item tool could be as good as a comprehensive assessment. Single‐item assessments of fatigue may have drawbacks, but more complex assessment methods may also be problematic in patients with advanced disease as they require some cognitive capacity, which is often lacking in a fatigue patient group. Excluding these studies would cause a new bias, as would excluding studies in end‐of‐life care and focused on patients in oncological care. Hence, we included and analysed these trials in our review. </p> </section> <section id="CD006788-sec-0040"> <h4 class="title">Excluded studies</h4> <p>The previous review, <a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>, excluded 23 studies and the review by <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a> excluded 14 studies. For this update, we had to exclude 49 studies in the final selection process after reading the manuscript. Reasons for exclusion were typically a lack of inclusion criteria match (e.g. fatigue defined as a secondary outcome; case series; not a RCT), investigation of fatigue attributed to narcotic‐induced sedation, data were a subset of another study which had been already included in the analysis, or data were not from patients with advanced disease. We listed these studies with the reason for exclusion in the <a href="./references#CD006788-sec-0101" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD006788-sec-0041"> <h3 class="title">Risk of bias in included studies</h3> <p>Some studies specifically described the randomisation and blinding procedure and we therefore considered them to have a minimal risk of bias concerning allocation concealment (e.g. <a href="./references#CD006788-bbs2-0012" title="CrucianiRA , ZhangJJ , ManolaJ , CellaD , AnsariB , FischMJ . L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology2012;30(31):3864-9. [PMID: 22987089]">Cruciani 2012</a>; <a href="./references#CD006788-bbs2-0032" title="RothAJ , NelsonC , RosenfeldB , ScherH , SlovinS , MorrisM , et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer2010;116(21):5102-10. [PMID: 20665492]">Roth 2010</a>). However, some studies did not specify these procedures, but used the terminology "double‐blind, randomised controlled trial", allowing the assumption of a low risk of bias (e.g. <a href="./references#CD006788-bbs2-0003" title="BarakY , MagalashviliD , DolgopiatMD , LadkaniD , NitzaniD , MazorZ , et al. Effect of alfacalcidol on fatigue in ms patients: a randomized, double-blind study. Neurology2014;82(10 Suppl):S23.004. ">Barak 2014</a>; <a href="./references#CD006788-bbs2-0021" title="LangeR , VolkmerM , HeesenC , LiepertJ . Modafinil effects in multiple sclerosis patients with fatigue. Journal of Neurology2009;256(4):645-50. [PMID: 19367356]">Lange 2009</a>). </p> <p>Considering the relatively small number of participants in most of the included studies, as well as the variety of instruments used, the results have to be interpreted with caution. The small numbers of participants may be a reason for a lack of stratification (for example, for relevant health conditions such as depression or sociodemographic data such as age or sex), which may alter the outcome as demonstrated by some investigators (<a href="./references#CD006788-bbs2-0110" title="EriksenJ , JensenMK , SjogrenP , EkholmO , RasmussenNK . Epidemiology of chronic non-malignant pain in Denmark. Pain2003;106(3):221-8. [PMID: 14659505]">Eriksen 2003</a>; <a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a>). </p> <p>We assessed each study using the Cochrane 'Risk of bias' tool. The findings are presented in the 'Risk of bias' graph (<a href="#CD006788-fig-0002">Figure 2</a>), which reviews the authors' judgements about each risk of bias item shown as percentages across all included studies, and the 'Risk of bias' summary (<a href="#CD006788-fig-0003">Figure 3</a>), which reviews the authors' judgements about each risk of bias item for each included study. </p> <div class="figure" id="CD006788-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006788-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006788-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about risk of bias items for each included study." data-id="CD006788-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about risk of bias items for each included study. </p> </div> </div> </div> <section id="CD006788-sec-0042"> <h4 class="title">Allocation</h4> <p>All studies reported randomisation, but no more than 23 included a proper description of the methods used (<a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a>; <a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a>; <a href="./references#CD006788-bbs2-0007" title="BrueraE , El OstaB , ValeroV , DriverLC , PeiBL , ShenL , et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2007;25(23):3475-81. [PMID: 17687152]">Bruera 2007</a>; <a href="./references#CD006788-bbs2-0011" title="CrucianiRA , DvorkinE , HomelP , CullineyB , MalamudS , LapinJ , et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. Journal of Pain and Symptom Management2009;37(4):622-31. [PMID: 18809275]">Cruciani 2009</a>; <a href="./references#CD006788-bbs2-0012" title="CrucianiRA , ZhangJJ , ManolaJ , CellaD , AnsariB , FischMJ . L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology2012;30(31):3864-9. [PMID: 22987089]">Cruciani 2012</a>; <a href="./references#CD006788-bbs2-0015" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungSH , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [PMID: 12743146]">Fisch 2003</a>; <a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a>; <a href="./references#CD006788-bbs2-0017" title="KerrCW , DrakeJ , MilchRA , BrazeauDA , SkretnyJA , BrazeauGA , et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. Journal of Pain and Symptom Management2012;43(1):68-77. [PMID: 20564068]">Kerr 2012</a>; <a href="./references#CD006788-bbs2-0018" title="KnappPE , StorerTW , HerbstKL , SinghAB , DzekovC , DzekovJ , et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. American Journal of Physiology. Endocrinology and Metabolism2008;294(6):E1135-43. [PMID: 18430965]">Knapp 2008</a>; <a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a>; <a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a>; <a href="./references#CD006788-bbs2-0026" title="RabkinJG , WagnerGJ , RabkinR . A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry2000;57(2):141-7; discussion 155-6. [PMID: 10665616]">Rabkin 2000</a>; <a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a>; <a href="./references#CD006788-bbs2-0028" title="RabkinJG , GordonPH , McElhineyM , RabkinR , ChewS , MitsumotoH . Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle and Nerve2009;39(3):297-303. [PMID: 19208404]">Rabkin 2009</a>; <a href="./references#CD006788-bbs2-0029" title="RabkinJG , McElhineyMC , RabkinR , McGrathP . Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. Journal of Clinical Psychiatry2010;71(6):707-15. [PMID: 20492840]">Rabkin 2010</a>; <a href="./references#CD006788-bbs2-0030" title="RabkinJG , McElhineyMC , RabkinR . Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics2011;52(4):328-36. [PMID: 21777715]">Rabkin 2011</a>; <a href="./references#CD006788-bbs2-0033" title="SemiglazovVF , StepulaVV , DudovA , SchnitkerJ , MengsU . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research2006;26(2B):1519-29. [PMID: 16619567]">Semiglazov 2006</a>; <a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a>; <a href="./references#CD006788-bbs2-0035" title="SimonsJP , AaronsonNK , VansteenkisteJF , ten VeldeGP , MullerMJ , DrenthBM , et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Journal of Clinical Oncology1996;14(4):1077-84. [PMID: 8648360]">Simons 1996</a>; <a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a>; <a href="./references#CD006788-bbs2-0040" title="VasconcelosOM , ProkhorenkoOA , SalajeghehMK , KelleyKF , LivorneseK , OlsenCH , et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology2007;68(20):1680-6. [PMID: 17502549]">Vasconcelos 2007</a>; <a href="./references#CD006788-bbs2-0043" title="WestmanG , BergmanB , AlbertssonM , KadarL , GustavssonG , ThaningL , et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer1999;35(4):586-95. [PMID: 10492632 ]">Westman 1999</a>; <a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a>). Only nine described the method used to conceal the allocation appropriately (<a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a>; <a href="./references#CD006788-bbs2-0007" title="BrueraE , El OstaB , ValeroV , DriverLC , PeiBL , ShenL , et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2007;25(23):3475-81. [PMID: 17687152]">Bruera 2007</a>; <a href="./references#CD006788-bbs2-0020" title="LacasseY , BeaudoinL , RousseauL , MaltaisF . Randomized trial of paroxetine in end-stage COPD. Monaldi Archives for Chest Disease2004;61(3):140-7. [PMID: 15679006]">Lacasse 2004</a>; <a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a>; <a href="./references#CD006788-bbs2-0028" title="RabkinJG , GordonPH , McElhineyM , RabkinR , ChewS , MitsumotoH . Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle and Nerve2009;39(3):297-303. [PMID: 19208404]">Rabkin 2009</a>; <a href="./references#CD006788-bbs2-0033" title="SemiglazovVF , StepulaVV , DudovA , SchnitkerJ , MengsU . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research2006;26(2B):1519-29. [PMID: 16619567]">Semiglazov 2006</a>; <a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a>; <a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a>; <a href="./references#CD006788-bbs2-0040" title="VasconcelosOM , ProkhorenkoOA , SalajeghehMK , KelleyKF , LivorneseK , OlsenCH , et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology2007;68(20):1680-6. [PMID: 17502549]">Vasconcelos 2007</a>; <a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a>). </p> </section> <section id="CD006788-sec-0043"> <h4 class="title">Blinding</h4> <p>Twenty studies were double‐blind (<a href="./references#CD006788-bbs2-0001" title="AshtariF , FatehiF , ShaygannejadV , ChitsazA . Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?Neurologia i Neurochirurgia Polska2009;43(5):428-32. [PMID: 11176767]">Ashtari 2009</a>; <a href="./references#CD006788-bbs2-0002" title="AuretKA , SchugSA , BremnerAP , BulsaraM . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. Journal of Pain and Symptom Management2009;37(4):613-21. [PMID: 18790598]">Auret 2009</a>; <a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a>; <a href="./references#CD006788-bbs2-0008" title="Butler JM Jr, CaseLD , AtkinsJ , FrizzellB , SandersG , GriffinP , et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics2007;69(5):1496-501. [PMID: 17869448]">Butler 2007</a>; <a href="./references#CD006788-bbs2-0011" title="CrucianiRA , DvorkinE , HomelP , CullineyB , MalamudS , LapinJ , et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. Journal of Pain and Symptom Management2009;37(4):622-31. [PMID: 18809275]">Cruciani 2009</a>; <a href="./references#CD006788-bbs2-0012" title="CrucianiRA , ZhangJJ , ManolaJ , CellaD , AnsariB , FischMJ . L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology2012;30(31):3864-9. [PMID: 22987089]">Cruciani 2012</a>; <a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a>; <a href="./references#CD006788-bbs2-0022" title="LouJS , DimitrovaDM , ParkBS , JohnsonSC , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clinical Neuropharmacology2009;32(6):305-10. [PMID: 19620846 ]">Lou 2009</a>; <a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a>; <a href="./references#CD006788-bbs2-0026" title="RabkinJG , WagnerGJ , RabkinR . A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry2000;57(2):141-7; discussion 155-6. [PMID: 10665616]">Rabkin 2000</a>; <a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a>; <a href="./references#CD006788-bbs2-0028" title="RabkinJG , GordonPH , McElhineyM , RabkinR , ChewS , MitsumotoH . Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle and Nerve2009;39(3):297-303. [PMID: 19208404]">Rabkin 2009</a>; <a href="./references#CD006788-bbs2-0029" title="RabkinJG , McElhineyMC , RabkinR , McGrathP . Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. Journal of Clinical Psychiatry2010;71(6):707-15. [PMID: 20492840]">Rabkin 2010</a>; <a href="./references#CD006788-bbs2-0030" title="RabkinJG , McElhineyMC , RabkinR . Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics2011;52(4):328-36. [PMID: 21777715]">Rabkin 2011</a>; <a href="./references#CD006788-bbs2-0032" title="RothAJ , NelsonC , RosenfeldB , ScherH , SlovinS , MorrisM , et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer2010;116(21):5102-10. [PMID: 20665492]">Roth 2010</a>; <a href="./references#CD006788-bbs2-0033" title="SemiglazovVF , StepulaVV , DudovA , SchnitkerJ , MengsU . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research2006;26(2B):1519-29. [PMID: 16619567]">Semiglazov 2006</a>; <a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a>; <a href="./references#CD006788-bbs2-0040" title="VasconcelosOM , ProkhorenkoOA , SalajeghehMK , KelleyKF , LivorneseK , OlsenCH , et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology2007;68(20):1680-6. [PMID: 17502549]">Vasconcelos 2007</a>; <a href="./references#CD006788-bbs2-0043" title="WestmanG , BergmanB , AlbertssonM , KadarL , GustavssonG , ThaningL , et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer1999;35(4):586-95. [PMID: 10492632 ]">Westman 1999</a>; <a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a>). The remainder did not provide sufficient information to assess risk of bias (unclear risk). </p> </section> <section id="CD006788-sec-0044"> <h4 class="title">Incomplete outcome data</h4> <p>There were only four studies lacking sufficient information to assess risk (unclear risk of bias) (<a href="./references#CD006788-bbs2-0008" title="Butler JM Jr, CaseLD , AtkinsJ , FrizzellB , SandersG , GriffinP , et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics2007;69(5):1496-501. [PMID: 17869448]">Butler 2007</a>; <a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a>; <a href="./references#CD006788-bbs2-0042" title="WeinshenkerBG , PenmanM , BassB , EbersGC , RiceGP . A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology1992;42(8):1468-71. [PMID: 1641137]">Weinshenker 1992</a>; <a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a>). We judged the remaining 41 studies to meet the criteria for low risk of bias. </p> </section> <section id="CD006788-sec-0045"> <h4 class="title">Other potential sources of bias</h4> <p>Treatment group size was an issue. Small studies are thought to be at increased risk of bias, probably because the conduct of small studies is more likely to be less rigorous, allowing critical criteria to be compromised. Only two of the treatment groups in this review were large enough to give a low risk of bias (<a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a>; <a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a>). We judged 14 studies to have an unclear risk (<a href="./references#CD006788-bbs2-0003" title="BarakY , MagalashviliD , DolgopiatMD , LadkaniD , NitzaniD , MazorZ , et al. Effect of alfacalcidol on fatigue in ms patients: a randomized, double-blind study. Neurology2014;82(10 Suppl):S23.004. ">Barak 2014</a>; <a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a>; <a href="./references#CD006788-bbs2-0007" title="BrueraE , El OstaB , ValeroV , DriverLC , PeiBL , ShenL , et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2007;25(23):3475-81. [PMID: 17687152]">Bruera 2007</a>; <a href="./references#CD006788-bbs2-0009" title="Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Canadian Journal of Neurological Sciences1987;14(3):273-8. [PMID: 2889518]">Canadian MSRG 1987</a>; <a href="./references#CD006788-bbs2-0012" title="CrucianiRA , ZhangJJ , ManolaJ , CellaD , AnsariB , FischMJ . L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology2012;30(31):3864-9. [PMID: 22987089]">Cruciani 2012</a>; <a href="./references#CD006788-bbs2-0013" title="Della CunaGR , PellegriniA , PiazziM . Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. European Journal of Cancer and Clinical Oncology1989;25(12):1817-21. [PMID: 2698804]">Della Cuna 1989</a>; <a href="./references#CD006788-bbs2-0015" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungSH , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [PMID: 12743146]">Fisch 2003</a>; <a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a>; <a href="./references#CD006788-bbs2-0029" title="RabkinJG , McElhineyMC , RabkinR , McGrathP . Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. Journal of Clinical Psychiatry2010;71(6):707-15. [PMID: 20492840]">Rabkin 2010</a>; <a href="./references#CD006788-bbs2-0033" title="SemiglazovVF , StepulaVV , DudovA , SchnitkerJ , MengsU . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research2006;26(2B):1519-29. [PMID: 16619567]">Semiglazov 2006</a>; <a href="./references#CD006788-bbs2-0035" title="SimonsJP , AaronsonNK , VansteenkisteJF , ten VeldeGP , MullerMJ , DrenthBM , et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Journal of Clinical Oncology1996;14(4):1077-84. [PMID: 8648360]">Simons 1996</a>; <a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a>; <a href="./references#CD006788-bbs2-0037" title="StankoffB , WaubantE , ConfavreuxC , EdanG , DebouverieM , RumbachL , et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology2005;64(7):1139-43. [PMID: 15824337]">Stankoff 2005</a>; <a href="./references#CD006788-bbs2-0043" title="WestmanG , BergmanB , AlbertssonM , KadarL , GustavssonG , ThaningL , et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer1999;35(4):586-95. [PMID: 10492632 ]">Westman 1999</a>). We judged the remainder to have a high risk of bias due to size. </p> </section> </section> <section id="CD006788-sec-0046"> <h3 class="title" id="CD006788-sec-0046">Effects of interventions</h3> <p>Most studies reported some benefit of the active treatment. However, there was often a substantial and very similar placebo effect. Further, reviewing only fatigue‐specific instruments (e.g. the Chalder Fatigue Scale (CFS), Fatigue Severity Scale (FSS), visual analogue scale (VAS) for fatigue), these benefits could not be confirmed in many cases. See also: <a href="#CD006788-sec-0018">Types of outcome measures</a>. In general, adverse reactions were mild and had little or no impact (<a href="#CD006788-tbl-0002">Table 2</a>)<b>.</b> </p> <div class="table" id="CD006788-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of adverse reactions associated with fatigue treatment</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug and indication</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Impact of adverse reaction</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Symptoms</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetyl‐L‐carnitine and amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (carnitine) and 5 (amantadine) of 36 patients withdrew</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carnitine: insomnia, nervousness<br/>Amantadine: nausea, dizziness </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 of 32 reported adverse reactions (versus 6 of 32 on placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hallucinations, nausea, gastric irritation, early morning wakening, hyperactivity, flu‐like illness </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0025" title="MurrayTJ . Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences1985;12(3):251-4. [PMID: 3902184]">Murray 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>— </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation, nausea, anxiety, influenza‐like illness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0010" title="CohenRA , FisherM . Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology1989;46(6):676-80. [PMID: 2730380]">Cohen 1989</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine, pemoline in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No severe adverse reaction (did not lead to withdrawal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline: palpitations, nausea, mood change, sleep disturbance, Amantadine: sleep disturbance, palpitations </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dextroamphetamine</p> <p>in HIV‐positive men with fatigue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of 23 patients discontinued during the 2 weeks of DB, PC RCT</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overstimulation, heart palpitation, sleep deprivation, loss of appetite and/or weight, headache. The authors reported that adverse reactions generally were "transient, reversible, and well managed with dose reduction; no serious medical side effects were reported" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0041" title="WagnerGJ , RabkinR . Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2000;61(6):436-40. [PMID: 10901342]">Wagner 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamphetamine in advanced cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drop‐out rate in verum group compared to placebo group was statistically not significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant increase in pulse rate. Transient increase of dry mouth, insomnia, tremor, anorexia on days 6 and 8 (of 8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0002" title="AuretKA , SchugSA , BremnerAP , BulsaraM . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. Journal of Pain and Symptom Management2009;37(4):613-21. [PMID: 18790598]">Auret 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 of 46 dropped out because of adverse reaction; 25% of patients did not tolerate pemoline well according to the authors </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most common side effects were anorexia, irritability, "jitteriness" and insomnia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0042" title="WeinshenkerBG , PenmanM , BassB , EbersGC , RiceGP . A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology1992;42(8):1468-71. [PMID: 1641137]">Weinshenker 1992</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse reaction</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea, transient epigastric pain (nausea, headache and diarrhoea occurred with placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate and pemoline in HIV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe side effects relatively uncommon; 5 withdrew (2 on methylphenidate, 2 on pemoline, 1 on placebo) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperactivity, jitteriness, dry mouth, rapid heart beat, difficulty sleeping, constipation, neuropathic pain (1 patient) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate in advanced cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No severe adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most pts reported insomnia, anorexia, restlessness, behavioural change and vertigo. Numbers in placebo groups were similar </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Donepezil in advanced cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No severe adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most pts reported anorexia, nausea, restlessness, dizziness, behaviour change, vertigo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0007" title="BrueraE , El OstaB , ValeroV , DriverLC , PeiBL , ShenL , et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2007;25(23):3475-81. [PMID: 17687152]">Bruera 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference in prevalence of adverse events reporting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most pts reported headache, insomnia, nausea, anxiety, dizziness, ataxia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0009" title="Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Canadian Journal of Neurological Sciences1987;14(3):273-8. [PMID: 2889518]">Canadian MSRG 1987</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paroxetine in end‐stage COPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 of 12 pts dropped out because of adverse effects related to the drug</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Somnolence was reported by 5 pts, constipation, nausea, headache tremor were rated by 2 pts each </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0020" title="LacasseY , BeaudoinL , RousseauL , MaltaisF . Randomized trial of paroxetine in end-stage COPD. Monaldi Archives for Chest Disease2004;61(3):140-7. [PMID: 15679006]">Lacasse 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone for HIV‐positive pts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 of 46 pts discontinued because of adverse reactions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne, irritability, insomnia, headache, nasal congestion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0026" title="RabkinJG , WagnerGJ , RabkinR . A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry2000;57(2):141-7; discussion 155-6. [PMID: 10665616]">Rabkin 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone and fluoxetine in HIV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine: diarrhoea, nausea, nonspecific discomfort<br/>Testosterone: sleepiness; all treatments: dry mouth, sleepiness, loose bowels </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil for HIV</p> <p>patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment‐emergent side effects were relatively uncommon</p> <p>CD4 cell count did not show either statistically or clinically significant changes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0029" title="RabkinJG , McElhineyMC , RabkinR , McGrathP . Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. Journal of Clinical Psychiatry2010;71(6):707-15. [PMID: 20492840]">Rabkin 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Armodafinil in HIV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Armodafinil was well tolerated, with few and transient adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The most common was headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0030" title="RabkinJG , McElhineyMC , RabkinR . Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics2011;52(4):328-36. [PMID: 21777715]">Rabkin 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine in post‐polio syndrome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insomnia was the commonest reported adverse reaction; dry mouth was noted by 1 patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0038" title="SteinDP , DambrosiaJM , DalakasMC . A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Annals of the New York Academy of Sciences1995;753:296-302. [PMID: 7611638]">Stein 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine in</p> <p>end‐stage renal</p> <p>disease (ESRD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse event was believed by the investigators to be certainly or probably drug‐related </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flu syndrome, injection‐site reaction, pain, pharyngitis,</p> <p>headache and hypertension showed no difference in frequency between L‐carnitine and placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0004" title="BrassEP , AdlerS , SietsemaKE , HiattWR , OrlandoAM , AmatoA , et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. American Journal of Kidney Diseases2001;37(5):1018-28. [PMID: 11325685]">Brass 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate in cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse effect</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some pts experienced nausea, vomiting, facial rash</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0014" title="EscalanteCP , MeyersC , ReubenJM , WangX , QiaoW , ManzulloE , et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer Journal (Sudbury, Mass.)2014;20(1):8-14. [PMID: 24445757]">Escalante 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine in cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A total of 16 adverse events were judged to be possibly due to the treatment and 6 to taking the placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic reaction, cardiac arrhythmia, dyspnoea, headaches, dizziness, mood change, myalgia, fever, diarrhoea, abdominal pain </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate in</p> <p>cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a significant difference in self reported toxicities (SED)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased levels of nervousness and appetite loss in the methylphenidate group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate in</p> <p>cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No severe adverse reaction</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (31%) men who started receiving methylphenidate had to be discontinued from the study due to increased blood pressure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0032" title="RothAJ , NelsonC , RosenfeldB , ScherH , SlovinS , MorrisM , et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer2010;116(21):5102-10. [PMID: 20665492]">Roth 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medroxyprogesterone acetate (MPA) in cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea and vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0035" title="SimonsJP , AaronsonNK , VansteenkisteJF , ten VeldeGP , MullerMJ , DrenthBM , et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Journal of Clinical Oncology1996;14(4):1077-84. [PMID: 8648360]">Simons 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid and amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid and amantadine are both well tolerated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The most common side effects of acetylsalicylic acid were nausea (n = 53) and transient epigastric pain (n = 51). The most common side effect of amantadine was also nausea (n = 51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil in cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil seemed to be well tolerated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most symptoms are nausea, vomiting, anxiety and headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 adverse events were probably related to study treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain grade 3 and vomiting grade 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>COPD = chronic obstructive pulmonary disease; DB = double‐blind; PC = placebo‐controlled; pts = participants RCT = randomised controlled trial </p> </div> </div> <section id="CD006788-sec-0047"> <h4 class="title">Acetyl‐L‐carnitine versus placebo</h4> <p>Acetyl‐L‐carnitine was compared with placebo in a study of 29 participants with cancer‐related fatigue, with no significant effect (<a href="./references#CD006788-bbs2-0011" title="CrucianiRA , DvorkinE , HomelP , CullineyB , MalamudS , LapinJ , et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. Journal of Pain and Symptom Management2009;37(4):622-31. [PMID: 18809275]">Cruciani 2009</a>). FACT‐fatigue mean scores were 15.7 (SD 10.6) at baseline and 22.2 (10.4) at week two (P value = 0.97). A recent study of 209 participants did not show statistically significant improvement in fatigue compared to placebo (<a href="./references#CD006788-bbs2-0012" title="CrucianiRA , ZhangJJ , ManolaJ , CellaD , AnsariB , FischMJ . L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology2012;30(31):3864-9. [PMID: 22987089]">Cruciani 2012</a>). The primary outcome, fatigue, measured using the Brief Fatigue Inventory (BFI), improved in both arms in comparison to baseline (L‐carnitine: ‐0.96, 95% confidence interval (CI) ‐1.32 to ‐0.60; placebo: ‐1.11, 95% CI ‐1.44 to ‐0.78). There were no statistically significant differences between the arms (P value <i>=</i> 0.57), while the secondary outcomes, including fatigue measured on the Functional Assessment for Chronic Illness Therapy ‐ Fatigue (FACIT‐F) scale, did not show a significant difference between arms, with a change in mean of 31.4 (standard deviation (SD) 9.21; L‐carnitine) versus 23.67 (SD 11.24; placebo) (P value= 0.61). </p> </section> <section id="CD006788-sec-0048"> <h4 class="title">Acetyl‐L‐carnitine versus amantadine</h4> <p>In another study of 36 participants, acetyl‐L‐carnitine was compared with amantadine in patients with multiple sclerosis (<a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a>). Improvement assessed with the FSS was superior with L‐carnitine compared with amantadine. In addition, L‐carnitine was better tolerated than amantadine. However, differences in the absolute changes in the FSS did not reach statistical significance and the number of responders was similar for both drugs. There was no significant change for the secondary outcome of clinical scale scores (Fatigue Impact Scale, Beck Depression Inventory and Social Experience Checklist). The fatigue domain of the Kidney Disease Questionnaire (KDQ) also significantly improved after 12 weeks and 24 weeks of carnitine therapy compared with placebo in 56 patients with end‐stage renal disease, but did not significantly affect the total score (<a href="./references#CD006788-bbs2-0004" title="BrassEP , AdlerS , SietsemaKE , HiattWR , OrlandoAM , AmatoA , et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. American Journal of Kidney Diseases2001;37(5):1018-28. [PMID: 11325685]">Brass 2001</a>). </p> </section> <section id="CD006788-sec-0049"> <h4 class="title">Acetylsalicylic acid versus placebo</h4> <p><a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a> was able to show significantly better relief of fatigue with 1300 mg/day of acetylsalicylic acid compared to placebo in 26 patients with multiple sclerosis. Wingerchuk et al used the Modified Fatigue Impact Scale (MFIS) and Kurtzke Expanded Disability Status Scale (KEDSS) as instruments. In another study of 52 patients with multiple sclerosis (<a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a>), 500 mg/day showed a significant decrease in FSS scores. We did not perform meta‐analysis due to the different doses and assessment instruments. </p> </section> <section id="CD006788-sec-0050"> <h4 class="title">Alfacalcidol versus placebo</h4> <p>A recent study using alfacalcidol 1 µg/day compared with placebo was conducted to treat fatigue in 158 multiple sclerosis patients. The Fatigue Impact Scale (FIS) total score decreased significantly. 'RAYS' quality of life assessments also improved significantly in the psychological and social subscale (<a href="./references#CD006788-bbs2-0003" title="BarakY , MagalashviliD , DolgopiatMD , LadkaniD , NitzaniD , MazorZ , et al. Effect of alfacalcidol on fatigue in ms patients: a randomized, double-blind study. Neurology2014;82(10 Suppl):S23.004. ">Barak 2014</a>). </p> </section> <section id="CD006788-sec-0051"> <h4 class="title">Amantadine versus placebo</h4> <p>Amantadine was used in seven studies of 370 participants with multiple sclerosis with heterogenous outcomes, showing a tendency towards improved outcomes with amantadine with different fatigue instruments and scales (<a href="./references#CD006788-bbs2-0001" title="AshtariF , FatehiF , ShaygannejadV , ChitsazA . Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?Neurologia i Neurochirurgia Polska2009;43(5):428-32. [PMID: 11176767]">Ashtari 2009</a>; <a href="./references#CD006788-bbs2-0009" title="Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Canadian Journal of Neurological Sciences1987;14(3):273-8. [PMID: 2889518]">Canadian MSRG 1987</a>; <a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a>; <a href="./references#CD006788-bbs2-0025" title="MurrayTJ . Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences1985;12(3):251-4. [PMID: 3902184]">Murray 1985</a>; <a href="./references#CD006788-bbs2-0031" title="RosenbergGA , AppenzellerO . Amantadine, fatigue, and multiple sclerosis. Archives of Neurology1988;45:1104-6. [PMID: 2972270]">Rosenberg 1988</a>; <a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a>; <a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a>). Amantadine was significantly better than placebo on the MS‐Fatigue scale. One study of 25 participants used amantadine post‐polio using the Fatigue Severity Scale (FSS) without proving efficacy (<a href="./references#CD006788-bbs2-0038" title="SteinDP , DambrosiaJM , DalakasMC . A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Annals of the New York Academy of Sciences1995;753:296-302. [PMID: 7611638]">Stein 1995</a>). </p> </section> <section id="CD006788-sec-0052"> <h4 class="title">Amantadine versus other drugs</h4> <p><a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a> tested amantadine against pemoline (93 participants). No difference between amantadine and pemoline was seen on the FSS. On the other hand, <a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a> performed a comparison of amantadine against acetyl‐L‐carnitine (ALCAR). ALCAR showed superior effect to amantadine. <a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a> tested amantadine against acetylsalicylic acid. Both groups showed a significant decrease in the FSS. </p> </section> <section id="CD006788-sec-0053"> <h4 class="title">Armodafinil versus placebo</h4> <p>Armodafinil was tested in 70 patients with HIV to evaluate its efficacy and safety for fatigue and depressive symptoms. In intention‐to‐treat analyses, the fatigue response rate to armodafinil was 75% and to placebo 26% (<a href="./references#CD006788-bbs2-0030" title="RabkinJG , McElhineyMC , RabkinR . Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics2011;52(4):328-36. [PMID: 21777715]">Rabkin 2011</a>). Armodafinil appeared to be effective in alleviating fatigue and was well tolerated. For the secondary endpoint depression, measured with the Hamilton Depression Rating Scale (HDRS) and Beck Depression Inventory (BDI), a significant effect was not shown. However, further multicentre studies with larger samples are needed. </p> </section> <section id="CD006788-sec-0054"> <h4 class="title">Dexamethasone versus placebo</h4> <p>Dexamethasone 4 mg was compared with placebo in a recent study to treat fatigue in 84 participants with advanced cancer. The study showed that dexamethasone was significantly superior to placebo (<a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a>). However, there was no significant difference in the improvement of individual symptoms on the Edmonton Symptom Assessment Scale (ESAS), psychological distress, anxiety scores on the Hospital Anxiety and Depression Scale (HADS) or HADS depression scores in the dexamethasone group compared with placebo. Further dexamethasone studies are needed. </p> </section> <section id="CD006788-sec-0055"> <h4 class="title">Dextroamphetamine versus placebo</h4> <p>Dextroamphetamine was compared with placebo to treat fatigue in a study of 39 cancer patients (<a href="./references#CD006788-bbs2-0002" title="AuretKA , SchugSA , BremnerAP , BulsaraM . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. Journal of Pain and Symptom Management2009;37(4):613-21. [PMID: 18790598]">Auret 2009</a>) and in 22 patients with HIV (<a href="./references#CD006788-bbs2-0041" title="WagnerGJ , RabkinR . Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2000;61(6):436-40. [PMID: 10901342]">Wagner 2000</a>). Neither study showed significant effects. The secondary outcome quality of life, which was measured using the McGill Quality of Life Questionnaire (MQOL), also showed no significant effect (<a href="./references#CD006788-bbs2-0002" title="AuretKA , SchugSA , BremnerAP , BulsaraM . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. Journal of Pain and Symptom Management2009;37(4):613-21. [PMID: 18790598]">Auret 2009</a>). </p> </section> <section id="CD006788-sec-0056"> <h4 class="title">Donepezil versus placebo</h4> <p>In a large study with 142 participants with cancer, donepezil significantly relieved fatigue intensity in both the intervention and control arms, with no significant difference as measured by the FACIT‐F scale. Edmonton Symptom Assessment Scale (ESAS) and sleep pattern assessment were also used as supplemental scales. Neither showed significant effects. Thus, donepezil did not appear to be superior to placebo (<a href="./references#CD006788-bbs2-0007" title="BrueraE , El OstaB , ValeroV , DriverLC , PeiBL , ShenL , et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2007;25(23):3475-81. [PMID: 17687152]">Bruera 2007</a>). </p> </section> <section id="CD006788-sec-0057"> <h4 class="title">Fluoxetine versus placebo</h4> <p>Another study of 129 patients with multiple sclerosis showed that 20 mg of fluoxetine over 12 weeks appeared to be superior to placebo as measured by the change in Functional Assessment of Cancer Therapy ‐ General (FACT‐G) scores. The fluoxetine group also showed significant improvement on the depression scale (P value = 0.0005) compared with placebo, which was measured using the Brief Zung Self‐Rating Depression Scale (BZSDS) (<a href="./references#CD006788-bbs2-0015" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungSH , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [PMID: 12743146]">Fisch 2003</a>). </p> </section> <section id="CD006788-sec-0058"> <h4 class="title">Fluoxetine versus testosterone</h4> <p>Fluoxetine was inferior to testosterone in 90 patients with HIV and fatigue, while the difference in the effect on depression, as measured with the HDRS, was non‐significant (P value = 0.38) (<a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a>). </p> </section> <section id="CD006788-sec-0059"> <h4 class="title">Medroxyprogesterone versus placebo</h4> <p>Medroxyprogesterone was tested in only one study of 134 participants using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC‐QLQ‐C30) (<a href="./references#CD006788-bbs2-0035" title="SimonsJP , AaronsonNK , VansteenkisteJF , ten VeldeGP , MullerMJ , DrenthBM , et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Journal of Clinical Oncology1996;14(4):1077-84. [PMID: 8648360]">Simons 1996</a>). The use of 500 mg twice a day over 12 weeks showed no significant effect. </p> </section> <section id="CD006788-sec-0060"> <h4 class="title">Megestrol acetate versus placebo</h4> <p>Megestrol acetate was tested in 255 patients with cancer. The administration of 320 mg/day for 12 weeks was performed to investigate the effect of megestrol acetate on quality of life, appetite, weight and survival. However, megestrol acetate does not appear to improve global quality of life as measured by the EORTC QLQ‐C30 (<a href="./references#CD006788-bbs2-0043" title="WestmanG , BergmanB , AlbertssonM , KadarL , GustavssonG , ThaningL , et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer1999;35(4):586-95. [PMID: 10492632 ]">Westman 1999</a>). </p> </section> <section id="CD006788-sec-0061"> <h4 class="title">Methylphenidate versus placebo</h4> <p>Five studies tested methylphenidate in 318 cancer patients (<a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a>; <a href="./references#CD006788-bbs2-0008" title="Butler JM Jr, CaseLD , AtkinsJ , FrizzellB , SandersG , GriffinP , et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics2007;69(5):1496-501. [PMID: 17869448]">Butler 2007</a>; <a href="./references#CD006788-bbs2-0014" title="EscalanteCP , MeyersC , ReubenJM , WangX , QiaoW , ManzulloE , et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer Journal (Sudbury, Mass.)2014;20(1):8-14. [PMID: 24445757]">Escalante 2014</a>; <a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a>; <a href="./references#CD006788-bbs2-0032" title="RothAJ , NelsonC , RosenfeldB , ScherH , SlovinS , MorrisM , et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer2010;116(21):5102-10. [PMID: 20665492]">Roth 2010</a>). Meta‐analysis was possible only for two studies (<a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a>; <a href="./references#CD006788-bbs2-0008" title="Butler JM Jr, CaseLD , AtkinsJ , FrizzellB , SandersG , GriffinP , et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics2007;69(5):1496-501. [PMID: 17869448]">Butler 2007</a>), which used FACIT‐F as the assessment tool in fatigue, comparing methylphenidate with placebo. The studies showed a slightly superior effect of methylphenidate compared to placebo (standardised mean difference (SMD) 0.49, 95% confidence interval (CI) 0.15 to 0.83; <a href="./references#CD006788-fig-0007" title="">Analysis 1.1</a>; <a href="#CD006788-fig-0004">Figure 4</a>). <a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a> used the Brief Fatigue Inventory (BFI) instrument, and could not show significant effects of methylphenidate (18 mg to 54 mg) compared with placebo. <a href="./references#CD006788-bbs2-0014" title="EscalanteCP , MeyersC , ReubenJM , WangX , QiaoW , ManzulloE , et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer Journal (Sudbury, Mass.)2014;20(1):8-14. [PMID: 24445757]">Escalante 2014</a> used a stable dose (18 mg) for two weeks. They reported that methylphenidate improved cancer‐related fatigue according to the BFI scores. The smallest dose was used by <a href="./references#CD006788-bbs2-0032" title="RothAJ , NelsonC , RosenfeldB , ScherH , SlovinS , MorrisM , et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer2010;116(21):5102-10. [PMID: 20665492]">Roth 2010</a> (5 mg to 30 mg). In this study, clinically significant improvement was seen on the BFI. </p> <div class="figure" id="CD006788-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Methylphenidate vs Placebo in cancer, outcome: 1.1 FACIT‐F score change." data-id="CD006788-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Methylphenidate vs Placebo in cancer, outcome: 1.1 FACIT‐F score change. </p> </div> </div> </div> <p>The other study of 30 participants using methylphenidate concerned the treatment of fatigue in multi‐type advanced disease (hospice) patients (<a href="./references#CD006788-bbs2-0017" title="KerrCW , DrakeJ , MilchRA , BrazeauDA , SkretnyJA , BrazeauGA , et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. Journal of Pain and Symptom Management2012;43(1):68-77. [PMID: 20564068]">Kerr 2012</a>). The study showed that methylphenidate was superior to placebo, although the improvement of the fatigue score was dose‐dependent, as measured by Piper Fatigue Scale, Visual Analogue Scale for Fatigue and ESAS. However, secondary outcomes of depressive symptoms, measured with the revised Beck Depression Inventory‐II (BDI‐II), the ESAS depression score and the Center for Epidemiologic Studies Depression Scale (CESD), showed no statistically significant differences. </p> <p>Methylphenidate was also investigated in 209 HIV patients and compared with pemoline and placebo (<a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a>). This study demonstrated a significantly higher number of responders using methylphenidate compared with placebo. </p> </section> <section id="CD006788-sec-0062"> <h4 class="title">Methylprednisolone versus placebo</h4> <p>Methylprednisolone (125 mg/day for eight weeks) was used with significant effect in only one study of 403 participants with cancer‐related fatigue (<a href="./references#CD006788-bbs2-0013" title="Della CunaGR , PellegriniA , PiazziM . Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. European Journal of Cancer and Clinical Oncology1989;25(12):1817-21. [PMID: 2698804]">Della Cuna 1989</a>). </p> </section> <section id="CD006788-sec-0063"> <h4 class="title">Mistletoe extract PS76A2 versus placebo</h4> <p>Mistletoe extract was tested in 337 patients with breast cancer (<a href="./references#CD006788-bbs2-0033" title="SemiglazovVF , StepulaVV , DudovA , SchnitkerJ , MengsU . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research2006;26(2B):1519-29. [PMID: 16619567]">Semiglazov 2006</a>). It showed a significant positive effect using the FACT‐G. </p> </section> <section id="CD006788-sec-0064"> <h4 class="title">Modafinil versus placebo</h4> <p>Modafinil has been explored for the treatment of fatigue in two studies of 704 patients with cancer (<a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a>; <a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a>). The <a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a> study showed a significant interaction between treatment condition (modafinil 200 mg/day) and baseline fatigue, where patients with severe baseline fatigue benefited from modafinil and patients with mild or moderate fatigue did not. A recent study demonstrated that both modafinil (100 to 200 mg/day) and placebo led to a clinically significant improvement in FACIT‐F scores (<a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a>). However, there was no significant difference between placebo and modafinil. </p> <p>Though modafinil has been tested in several studies in multiple sclerosis, we found only two controlled trials (<a href="./references#CD006788-bbs2-0021" title="LangeR , VolkmerM , HeesenC , LiepertJ . Modafinil effects in multiple sclerosis patients with fatigue. Journal of Neurology2009;256(4):645-50. [PMID: 19367356]">Lange 2009</a>; <a href="./references#CD006788-bbs2-0037" title="StankoffB , WaubantE , ConfavreuxC , EdanG , DebouverieM , RumbachL , et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology2005;64(7):1139-43. [PMID: 15824337]">Stankoff 2005</a>). The <a href="./references#CD006788-bbs2-0037" title="StankoffB , WaubantE , ConfavreuxC , EdanG , DebouverieM , RumbachL , et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology2005;64(7):1139-43. [PMID: 15824337]">Stankoff 2005</a> study included a larger number of participants (n = 115), but failed to demonstrate the superiority of modafinil versus placebo. <a href="./references#CD006788-bbs2-0021" title="LangeR , VolkmerM , HeesenC , LiepertJ . Modafinil effects in multiple sclerosis patients with fatigue. Journal of Neurology2009;256(4):645-50. [PMID: 19367356]">Lange 2009</a> included only 21 participants and stated that they used a subpopulation of a larger trial. Thus, although there was a clear beneficial effect of modafinil, this result must be interpreted with caution due to the small participant numbers. Meta‐analysis of these two studies also failed to demonstrate a significant effect, with a SMD of ‐0.14 (95% CI ‐0.48 to 0.21; <a href="./references#CD006788-fig-0008" title="">Analysis 2.1</a>; <a href="#CD006788-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD006788-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Modafinil in multiple sclerosis, outcome: 4.1 Modafinil." data-id="CD006788-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Modafinil in multiple sclerosis, outcome: 4.1 Modafinil.</p> </div> </div> </div> <p>Modafinil was also tested for the treatment of fatigue in 33 participants with post‐polio syndrome (<a href="./references#CD006788-bbs2-0040" title="VasconcelosOM , ProkhorenkoOA , SalajeghehMK , KelleyKF , LivorneseK , OlsenCH , et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology2007;68(20):1680-6. [PMID: 17502549]">Vasconcelos 2007</a>). However, in this study modafinil failed to demonstrate superiority over placebo. </p> <p>There was also a trial using modafinil for fatigue in 105 HIV/AIDS patients (<a href="./references#CD006788-bbs2-0029" title="RabkinJG , McElhineyMC , RabkinR , McGrathP . Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. Journal of Clinical Psychiatry2010;71(6):707-15. [PMID: 20492840]">Rabkin 2010</a>). In the intention‐to‐treat analyses, the fatigue response rate to modafinil was 73% and to placebo 28%; the attrition rate was 9%. Secondary endpoints (depression), including the Hamilton Depression Rating Scale (HDRS) and Beck Depression Inventory (BDI), did not show a significant effect. </p> </section> <section id="CD006788-sec-0065"> <h4 class="title">Paroxetine versus placebo</h4> <p>Paroxetine was tested in a study of 479 patients with cancer (<a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a>), and a study of 15 patients with end‐stage chronic obstructive pulmonary disease (COPD; <a href="./references#CD006788-bbs2-0020" title="LacasseY , BeaudoinL , RousseauL , MaltaisF . Randomized trial of paroxetine in end-stage COPD. Monaldi Archives for Chest Disease2004;61(3):140-7. [PMID: 15679006]">Lacasse 2004</a>). Neither study showed significant effects. However, the Center for Epidemiological Studies Depression (CESD) score, controlling baseline depression scores, confirmed that the dose of paroxetine provided was more effective than placebo in reducing depression (P value = 0.001). </p> </section> <section id="CD006788-sec-0066"> <h4 class="title">Pemoline versus placebo</h4> <p>Pemoline was used for the treatment of fatigue in 41 participants with multiple sclerosis. However, in this study pemoline failed to demonstrate superiority over placebo (<a href="./references#CD006788-bbs2-0042" title="WeinshenkerBG , PenmanM , BassB , EbersGC , RiceGP . A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology1992;42(8):1468-71. [PMID: 1641137]">Weinshenker 1992</a>). </p> </section> <section id="CD006788-sec-0067"> <h4 class="title">Pemoline versus other drugs</h4> <p>Pemoline was tested in 93 patients with multiple sclerosis and severe fatigue (<a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a>). The drug did not appear to be superior to placebo. One study with HIV patients compared pemoline to methylphenidate and to a placebo (<a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a>). The <a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a> study demonstrated a significantly higher number of responders with pemoline and methylphenidate compared with placebo. </p> <p>Meta‐analysis was possible for two studies in multiple sclerosis patients as they all included a control group with placebo and reported continuous outcome indicators (<a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a>; <a href="./references#CD006788-bbs2-0042" title="WeinshenkerBG , PenmanM , BassB , EbersGC , RiceGP . A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology1992;42(8):1468-71. [PMID: 1641137]">Weinshenker 1992</a>). There was no superior effect of pemoline (SMD ‐0.02; 95% CI ‐0.12 to 0.08; <a href="#CD006788-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD006788-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Pemoline in multiple sclerosis, outcome: 3.1 Fatigue score change." data-id="CD006788-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Pemoline in multiple sclerosis, outcome: 3.1 Fatigue score change. </p> </div> </div> </div> <p>However, the US Food and Drug Administration (FDA) has decided to withdraw pemoline products (marketed as Cylert) due to the risk of liver toxicity, which outweighs the benefits of the drug. All manufacturers have agreed to stop the sale and marketing of pemoline (<a href="./references#CD006788-bbs2-0113" title="US Food and Drug Administration. Information for Healthcare Professionals: Pemoline Tablets and Chewable Tablets (marketed as Cylert). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126461.htm 2005 (accessed 3 September 2014).">FDA 2005</a>). </p> </section> <section id="CD006788-sec-0068"> <h4 class="title">Testosterone versus placebo</h4> <p>Testosterone cypionate was investigated in 208 patients with HIV in three studies by the same workgroup (<a href="./references#CD006788-bbs2-0018" title="KnappPE , StorerTW , HerbstKL , SinghAB , DzekovC , DzekovJ , et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. American Journal of Physiology. Endocrinology and Metabolism2008;294(6):E1135-43. [PMID: 18430965]">Knapp 2008</a>; <a href="./references#CD006788-bbs2-0026" title="RabkinJG , WagnerGJ , RabkinR . A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry2000;57(2):141-7; discussion 155-6. [PMID: 10665616]">Rabkin 2000</a>; <a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a>). The older study included HIV patients with symptoms of hypogonadism and found that testosterone relieved these symptoms in patients with fatigue at baseline (<a href="./references#CD006788-bbs2-0026" title="RabkinJG , WagnerGJ , RabkinR . A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry2000;57(2):141-7; discussion 155-6. [PMID: 10665616]">Rabkin 2000</a>). However, fatigue intensity on the CFS merely showed a positive trend, but no significant difference from placebo. The newer study did not show any significant benefit of testosterone compared to fluoxetine or placebo (<a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a>). Only <a href="./references#CD006788-bbs2-0018" title="KnappPE , StorerTW , HerbstKL , SinghAB , DzekovC , DzekovJ , et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. American Journal of Physiology. Endocrinology and Metabolism2008;294(6):E1135-43. [PMID: 18430965]">Knapp 2008</a> showed superiority of testosterone over placebo. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006788-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006788-sec-0069"></div> <p>This review updates the original review 'Pharmacological treatments for fatigue associated with palliative care' (<a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>) and also incorporates 'Drug therapy for the management of cancer‐related fatigue' (<a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a>). <a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a> and <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a> included 22 and 31 studies, respectively. This updated review includes seven studies from <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a> and 22 studies from <a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>. </p> <section id="CD006788-sec-0070"> <h3 class="title" id="CD006788-sec-0070">Summary of main results</h3> <p>This systematic review update identified 45 studies for inclusion, with a wide range of underlying diseases and drug interventions. Treatment results pointed to weak and inconclusive evidence for the efficacy of amantadine, pemoline and modafinil in multiple sclerosis and for carnitine and donepezil in cancer‐related fatigue. Methylphenidate and pemoline seem to be effective in patients with HIV, but this is based only on one study per intervention, with only a moderate number of participants in each study. Meta‐analysis shows an estimated superior effect for methylphenidate in cancer‐related fatigue, but not for pemoline and modafinil in multiple sclerosis. Therapeutic effects could not be described for dexamphetamine, paroxetine or testosterone. </p> <p>Acetylsalicylic acid demonstrated surprising efficacy in patients with multiple sclerosis (<a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a>; <a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a>). However, this result was not supported by other studies. For clinical recommendation, further research confirming this positive effect is needed. </p> <p>Some studies used other drugs, for example mistletoe extract, megestrol acetate and medroxyprogesterone acetate (<a href="./references#CD006788-bbs2-0033" title="SemiglazovVF , StepulaVV , DudovA , SchnitkerJ , MengsU . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research2006;26(2B):1519-29. [PMID: 16619567]">Semiglazov 2006</a>; <a href="./references#CD006788-bbs2-0035" title="SimonsJP , AaronsonNK , VansteenkisteJF , ten VeldeGP , MullerMJ , DrenthBM , et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Journal of Clinical Oncology1996;14(4):1077-84. [PMID: 8648360]">Simons 1996</a>; <a href="./references#CD006788-bbs2-0043" title="WestmanG , BergmanB , AlbertssonM , KadarL , GustavssonG , ThaningL , et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer1999;35(4):586-95. [PMID: 10492632 ]">Westman 1999</a>), but these studies lacked strong evidence and the clinical use of these drugs is rather rare. Further studies need to demonstrate their clinical efficacy. </p> <p>The available evidence from randomised controlled trials (RCTs) is scarce, even though there is a surplus of case reports and uncontrolled trials. It has to be kept in mind that many of the included studies involved only a small number of participants (<a href="./references#CD006788-bbs2-0020" title="LacasseY , BeaudoinL , RousseauL , MaltaisF . Randomized trial of paroxetine in end-stage COPD. Monaldi Archives for Chest Disease2004;61(3):140-7. [PMID: 15679006]">Lacasse 2004</a>; <a href="./references#CD006788-bbs2-0031" title="RosenbergGA , AppenzellerO . Amantadine, fatigue, and multiple sclerosis. Archives of Neurology1988;45:1104-6. [PMID: 2972270]">Rosenberg 1988</a>), and did not follow a consistent research methodology. In some cases the investigated population was very heterogenous and any outcome may have been associated with depression (<a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a>; <a href="./references#CD006788-bbs2-0041" title="WagnerGJ , RabkinR . Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2000;61(6):436-40. [PMID: 10901342]">Wagner 2000</a>), making it difficult to distinguish from primary fatigue. Fatigue often occurs in clusters, and fatigue and emotional distress are often concurrent factors. The National Comprehensive Cancer Network (NCCN) guidelines discuss studies, some of which show fatigue as an independent factor of depression, while others report moderate correlation. The 2014 NCCN guidelines recommended that the psychostimulant methylphenidate may be considered with caution for the pharmacological treatment of fatigue in selected patients. However, corticosteroids are recommended for short‐term but not long‐term therapy, due to their toxicity (<a href="./references#CD006788-bbs2-0127" title="National Comprehensive Cancer Network. Cancer related fatigue. www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf (accessed 30 October 2014).">NCCN 2014</a>). </p> <p>Treatment of secondary fatigue should be initiated with the treatment of the underlying cause. Some causes of secondary fatigue, such as anaemia, depression, infection, dehydration, malnutrition, hypercalcaemia, hypomagnesaemia, other metabolic disorders or the side effects of treatment with opioids and other sedative drugs, should also be treated, though little evidence from randomised trials is available on the efficacy of these treatments (<a href="./references#CD006788-bbs2-0108" title="RadbruchL , StrasserF , ElsnerF , GonçalvesJF , LøgeJ , KaasaS , et al, Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients -- an EAPC approach. Palliative Medicine2008;22:13-32. [DOI: 10.1177/0269216307085183] [PMID: 18216074]">EAPC 2008</a>). </p> <p>This review only included studies specifically focusing on palliative care in patients with advanced disease with the aim of relieving fatigue. Studies investigating curative treatment (e.g. treatment of early breast cancer) and fatigue directly related to treatment were not included in this review. </p> <p>In addition, the results of the literature search indicate that recent research interest focuses on modafinil (eight studies) and its use in fatigue management for palliative care patients. This may be an interesting future perspective. </p> </section> <section id="CD006788-sec-0071"> <h3 class="title" id="CD006788-sec-0071">Potential biases in the review process</h3> <p>None of the authors of this review were involved in any of the excluded or included studies. In addition, none of the authors has any conflict of interest. Our search strategy was as comprehensive as possible. All studies were independently assessed for inclusion by two review authors so we are confident that we have included all relevant studies and attempted to reduce bias in the review process. </p> <p>Due to difficulties in conducting these types of trials for any of these drugs, trials may not have been published at all. Therefore, there is the potential for publication bias in this review. However, by contacting experts in this field we have attempted to reduce this bias as much as possible. </p> </section> <section id="CD006788-sec-0072"> <h3 class="title" id="CD006788-sec-0072">Agreements and disagreements with other studies or reviews</h3> <p>There have been two previous Cochrane Reviews (<a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a>; <a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a>), which are merged in this systematic review using a new search strategy to increase its coverage. <a href="./references#CD006788-bbs2-0124" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] [20614448 ]">Minton 2010</a> concluded in their last published version that there is increasing evidence that psychostimulant trials improve cancer‐related fatigue at a clinically meaningful level. This review described the need for a large‐scale RCT of methylphenidate to confirm the preliminary results from their review. They recommended haemopoietic growth factors for the treatment of cancer‐related fatigue. However, with new safety data indicating increased adverse outcomes, these drugs can no longer be recommended in the treatment of cancer‐related fatigue (<a href="./references#CD006788-bbs2-0097" title="BennettCL , SilverSM , DjulbegovicB , SamarasAT , BlauCA , GleasonKJ , et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA2008;299(8):914-24. [DOI: 10.1001/jama.299.8.914] [PMID: 18314434]">Bennet 2008</a>; <a href="./references#CD006788-bbs2-0098" title="BohliusJ , SchmidlinK , BrillantC , SchwarzerG , TrelleS , SeidenfeldJ , et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet2009;373(9674):1532-42. [DOI: 10.1016/S0140-6736(09)60502-X] [PMID: 19410717]">Bohlius 2009</a>; <a href="./references#CD006788-bbs2-0108" title="RadbruchL , StrasserF , ElsnerF , GonçalvesJF , LøgeJ , KaasaS , et al, Research Steering Committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients -- an EAPC approach. Palliative Medicine2008;22:13-32. [DOI: 10.1177/0269216307085183] [PMID: 18216074]">EAPC 2008</a>; <a href="./references#CD006788-bbs2-0115" title="GlaspyJA . Erythropoietin in cancer patients. Annual Review of Medicine2009;60:181-92. [DOI: 10.1146/annurev.med.60.050307.110718] [PMID: 18980468]">Glaspy 2009</a>; <a href="./references#CD006788-bbs2-0143" title="TonelliM , HemmelgarnB , ReimanT , MannsB , ReaumeMN , LloydA , et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. Canadian Medical Association Journal2009;180(11):62-71. [DOI: 10.1503/cmaj.090470] [PMID: 19407261]">Tonelli 2009</a>). <a href="./references#CD006788-bbs2-0148" title="Peuckmann-PostV , ElsnerF , KrummN , TrottenbergP , RadbruchL . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006788.pub2]">Peuckmann‐Post 2011</a> concluded that, based on limited evidence, they could not recommend a specific drug for the treatment of fatigue in palliative care patients. The review pointed out that until 2009, corticosteroids had not been the focus of research on fatigue treatment, although these drugs were frequently used in clinical practice. This review also stated that fatigue research seems to focus on modafinil, which may be beneficial, although there is no evidence. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006788-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006788-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006788-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006788-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006788-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about risk of bias items for each included study." data-id="CD006788-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about risk of bias items for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006788-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Methylphenidate vs Placebo in cancer, outcome: 1.1 FACIT‐F score change." data-id="CD006788-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Methylphenidate vs Placebo in cancer, outcome: 1.1 FACIT‐F score change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006788-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Modafinil in multiple sclerosis, outcome: 4.1 Modafinil." data-id="CD006788-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Modafinil in multiple sclerosis, outcome: 4.1 Modafinil.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006788-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Pemoline in multiple sclerosis, outcome: 3.1 Fatigue score change." data-id="CD006788-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Pemoline in multiple sclerosis, outcome: 3.1 Fatigue score change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006788-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methylphenidate versus placebo in cancer, Outcome 1: FACIT‐F score change" data-id="CD006788-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Methylphenidate versus placebo in cancer, Outcome 1: FACIT‐F score change</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references#CD006788-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006788-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Modafinil versus placebo in multiple sclerosis, Outcome 1: Fatigue score change" data-id="CD006788-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Modafinil versus placebo in multiple sclerosis, Outcome 1: Fatigue score change </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references#CD006788-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006788-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/urn:x-wiley:14651858:media:CD006788:CD006788-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pemoline versus placebo in multiple sclerosis, Outcome 1: Fatigue score change" data-id="CD006788-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_t/tCD006788-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Pemoline versus placebo in multiple sclerosis, Outcome 1: Fatigue score change </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references#CD006788-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/media/CDSR/CD006788/image_n/nCD006788-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD006788-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Drug treatment of fatigue: Populations, substances and outcome measures</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Patient population</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Substance</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome measures</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue in advanced cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amphetamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI, McGill Quality of Life Questionnaire, ECOG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0002" title="AuretKA , SchugSA , BremnerAP , BulsaraM . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. Journal of Pain and Symptom Management2009;37(4):613-21. [PMID: 18790598]">Auret 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACT‐An, LASA, MMSE, KPS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0011" title="CrucianiRA , DvorkinE , HomelP , CullineyB , MalamudS , LapinJ , et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. Journal of Pain and Symptom Management2009;37(4):622-31. [PMID: 18809275]">Cruciani 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI, FACIT‐F, depression and pain instrument</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0012" title="CrucianiRA , ZhangJJ , ManolaJ , CellaD , AnsariB , FischMJ . L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology2012;30(31):3864-9. [PMID: 22987089]">Cruciani 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paroxetine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSC, MFI, Monopolar Profile of Mood States</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0024" title="MorrowGR , HickokJT , RoscoeJA , RaubertasRF , AndrewsPL , FlynnPJ , et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology2003;21(24):4635-41. [PMID: 14673053]">Morrow 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F, ESAS, daily diary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function, FACIT‐F, CESD, MMSE, KPS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0008" title="Butler JM Jr, CaseLD , AtkinsJ , FrizzellB , SandersG , GriffinP , et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics2007;69(5):1496-501. [PMID: 17869448]">Butler 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI, SED, SF‐36 vitality subscale, LASA, PSQI, SGIC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0032" title="RothAJ , NelsonC , RosenfeldB , ScherH , SlovinS , MorrisM , et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer2010;116(21):5102-10. [PMID: 20665492]">Roth 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0014" title="EscalanteCP , MeyersC , ReubenJM , WangX , QiaoW , ManzulloE , et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer Journal (Sudbury, Mass.)2014;20(1):8-14. [PMID: 24445757]">Escalante 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Donepezil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT‐F, ESAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0007" title="BrueraE , El OstaB , ValeroV , DriverLC , PeiBL , ShenL , et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2007;25(23):3475-81. [PMID: 17687152]">Bruera 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylprednisolone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NOSIE, LASA, Physician's Global</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0013" title="Della CunaGR , PellegriniA , PiazziM . Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. European Journal of Cancer and Clinical Oncology1989;25(12):1817-21. [PMID: 2698804]">Della Cuna 1989</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BFI, ESS, POMS‐DD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACIT, ESS, HADS, QOL‐LAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACT‐G</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0015" title="FischMJ , LoehrerPJ , KristellerJ , PassikS , JungSH , ShenJ , et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. Journal of Clinical Oncology2003;21(10):1937-43. [PMID: 12743146]">Fisch 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standardised Mistletoe extract</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACT‐G</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0033" title="SemiglazovVF , StepulaVV , DudovA , SchnitkerJ , MengsU . Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research2006;26(2B):1519-29. [PMID: 16619567]">Semiglazov 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medroxyprogesterone acetate (MPA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FACT‐G</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0035" title="SimonsJP , AaronsonNK , VansteenkisteJF , ten VeldeGP , MullerMJ , DrenthBM , et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Journal of Clinical Oncology1996;14(4):1077-84. [PMID: 8648360]">Simons 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Megestrol acetate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC‐QLQ‐C30 instrument</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0043" title="WestmanG , BergmanB , AlbertssonM , KadarL , GustavssonG , ThaningL , et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer1999;35(4):586-95. [PMID: 10492632 ]">Westman 1999</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue in amyotrophic lateral sclerosis (ALS)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGI‐E, FSS, ESS, BDI, RFS, VAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0028" title="RabkinJG , GordonPH , McElhineyM , RabkinR , ChewS , MitsumotoH . Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle and Nerve2009;39(3):297-303. [PMID: 19208404]">Rabkin 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue in HIV/AIDS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Armodafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGI‐I, FSS, HDRS, BDI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0030" title="RabkinJG , McElhineyMC , RabkinR . Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics2011;52(4):328-36. [PMID: 21777715]">Rabkin 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGI‐I, FSS, HDRS, BDI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amphetamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCID; HDRS, BFI, BHS, VAS for mood, CFS, VAS for energy level</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0041" title="WagnerGJ , RabkinR . Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2000;61(6):436-40. [PMID: 10901342]">Wagner 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGIS "was expanded to include ratings of energy, as well as mood and a global rating. Significant improvement was defined as score of 1 or 2 on CGIS"; HDRS, CFS </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGIS ratings for libido, mood, energy and erectile function; CFS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0026" title="RabkinJG , WagnerGJ , RabkinR . A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry2000;57(2):141-7; discussion 155-6. [PMID: 10665616]">Rabkin 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body composition, muscle strength and physical function, MOS‐30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0018" title="KnappPE , StorerTW , HerbstKL , SinghAB , DzekovC , DzekovJ , et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. American Journal of Physiology. Endocrinology and Metabolism2008;294(6):E1135-43. [PMID: 18430965]">Knapp 2008</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body composition, muscle strength and physical function, MOS‐30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue in multiple sclerosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS‐F, KEDSS, mBDI; tolerance of adverse effects and checklist to identify their nature</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0042" title="WeinshenkerBG , PenmanM , BassB , EbersGC , RiceGP . A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology1992;42(8):1468-71. [PMID: 1641137]">Weinshenker 1992</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, MS Specific Fatigue Scale, subjective response (verbal rating)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, Fatigue Impact Scale, Beck Depression Inventory, Social Experience Checklist</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, Fatigue Impact Scale, Beck Depression Inventory, Social Experience Checklist</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS; mBDI, "Stroop Interference Test" (attentional measure of freedom from distracting information) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0010" title="CohenRA , FisherM . Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology1989;46(6):676-80. [PMID: 2730380]">Cohen 1989</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS; mBDI, "Stroop Interference Test" (attentional measure of freedom from distracting information) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0025" title="MurrayTJ . Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences1985;12(3):251-4. [PMID: 3902184]">Murray 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS, patient preference</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0031" title="RosenbergGA , AppenzellerO . Amantadine, fatigue, and multiple sclerosis. Archives of Neurology1988;45:1104-6. [PMID: 2972270]">Rosenberg 1988</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KEDSS; BDI; VAS‐F</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0009" title="Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Canadian Journal of Neurological Sciences1987;14(3):273-8. [PMID: 2889518]">Canadian MSRG 1987</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0001" title="AshtariF , FatehiF , ShaygannejadV , ChitsazA . Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?Neurologia i Neurochirurgia Polska2009;43(5):428-32. [PMID: 11176767]">Ashtari 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFIS, KEDSS, CESD, SGIC, FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, alertness test, NHPT, TMS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0021" title="LangeR , VolkmerM , HeesenC , LiepertJ . Modafinil effects in multiple sclerosis patients with fatigue. Journal of Neurology2009;256(4):645-50. [PMID: 19367356]">Lange 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFIS, VAS‐F, ESS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0037" title="StankoffB , WaubantE , ConfavreuxC , EdanG , DebouverieM , RumbachL , et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology2005;64(7):1139-43. [PMID: 15824337]">Stankoff 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS, VAS‐F, FIS, SF‐36 QOL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0040" title="VasconcelosOM , ProkhorenkoOA , SalajeghehMK , KelleyKF , LivorneseK , OlsenCH , et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology2007;68(20):1680-6. [PMID: 17502549]">Vasconcelos 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FIS, QOL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alfacalcidol (Vit. D)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FIS, QOL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0003" title="BarakY , MagalashviliD , DolgopiatMD , LadkaniD , NitzaniD , MazorZ , et al. Effect of alfacalcidol on fatigue in ms patients: a randomized, double-blind study. Neurology2014;82(10 Suppl):S23.004. ">Barak 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage renal</b> </p> <p><b>disease (ESRD)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>KDQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0004" title="BrassEP , AdlerS , SietsemaKE , HiattWR , OrlandoAM , AmatoA , et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. American Journal of Kidney Diseases2001;37(5):1018-28. [PMID: 11325685]">Brass 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parkinson's disease</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MFI, ESS, CESD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0022" title="LouJS , DimitrovaDM , ParkBS , JohnsonSC , EatonR , ArnoldG , et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clinical Neuropharmacology2009;32(6):305-10. [PMID: 19620846 ]">Lou 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Multi‐type advanced</b> </p> <p><b>disease (hospice</b> </p> <p><b>patients)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PFS, VAS‐F, ESAS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0017" title="KerrCW , DrakeJ , MilchRA , BrazeauDA , SkretnyJA , BrazeauGA , et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. Journal of Pain and Symptom Management2012;43(1):68-77. [PMID: 20564068]">Kerr 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>End‐stage COPD</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paroxetine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36, chronic respiratory questionnaire: 1 of 4 domains was fatigue, geriatric depression scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0020" title="LacasseY , BeaudoinL , RousseauL , MaltaisF . Randomized trial of paroxetine in end-stage COPD. Monaldi Archives for Chest Disease2004;61(3):140-7. [PMID: 15679006]">Lacasse 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Postpolio syndrome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FSS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0038" title="SteinDP , DambrosiaJM , DalakasMC . A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Annals of the New York Academy of Sciences1995;753:296-302. [PMID: 7611638]">Stein 1995</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>BDI = Beck Depression Inventory; BFI = Brief Fatigue Inventory; BHS = Beck Hopelessness Scale; CESD = Center for Epidemiologic Studies Depression; CFS = Chalder Fatigue Scale; DB = double‐blind; ECOG = performance status according to the Eastern Cooperative Oncology Group Scale; EORTC‐QLQ‐C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; ESAS = Edmonton Symptom Assessment System; ESS = Epworth Sleepiness Scale; FACIT‐F = Functional Assessment for Chronic Illness Therapy ‐ Fatigue; FACT‐An = Functional Assessment of Cancer Therapy ‐ Anaemia; FIS = Fatigue Impact Scale; FSC = Fatigue Symptom Checklist; FSS = Fatigue Severity Scale; HADS = Hospital Anxiety and Depression Scale; HDRS = Hamilton Depression Rating Scale; IM = intramuscular; ITT = intention‐to‐treat; IV = intravenous; KDQ = Kidney Disease Questionnaire; KEDSS = Kurtzke Expanded Disability Status Scale; KPS = Karnofsky Performance Status; LASA = Linear Analogue Scale Assessments; MAF = Multidimensional Assessment of Fatigue; mBDI = Modified Beck Depression Inventory; MFI = Multidimensional Fatigue Inventory; MMSE = Mini Mental State Examination; MOS‐30 = Medical Outcomes Study‐Short Form 30; MPMM = Monopolar Profile of Mood States; MS = multiple sclerosis; MS SFS = Multiple Sclerosis Specific Fatigue Scale; NHPT = Nine Hole Peg Test; NOSIE = Nurses' Observational Scale for Inpatient Evaluation; NRS = numeric rating scale; PC = placebo‐controlled; PFS = Piper Fatigue Scale; PO = per oral; POMS‐DD = Depression‐Dejection subscale of the Profile of Mood States; prn = as needed; PSQI = Pittsburgh Sleep Quality Index; pts = participants; QOL = RAYS quality of life; QOL‐LAS = quality of life linear analogue scale; RCT = randomised controlled trial; RFS = Role Function Scale; RT = radiation therapy; sc = subcutaneous; SCID = depression according to Structured Clinical Interview for DSM‐IV; SD = standard deviation; SE = standard error; SEC = Social Experience Checklist; SED = Symptom Experience Diary; SF‐36 = Short Form‐36; SGIC = Subject Global Impression of Change; TMS = transcranial magnetic Social Experience Checklist; VAS = visual analogue scale; VAS‐F = visual analogue scale ‐ fatigue </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Drug treatment of fatigue: Populations, substances and outcome measures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006788-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of adverse reactions associated with fatigue treatment</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug and indication</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Impact of adverse reaction</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Symptoms</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetyl‐L‐carnitine and amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (carnitine) and 5 (amantadine) of 36 patients withdrew</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carnitine: insomnia, nervousness<br/>Amantadine: nausea, dizziness </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0039" title="TomassiniV , PozzilliC , OnestiE , PasqualettiP , MarinelliF , PisaniA , et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of the Neurological Sciences2004;218(1-2):103-8. [PMID: 14759641]">Tomassini 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 of 32 reported adverse reactions (versus 6 of 32 on placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hallucinations, nausea, gastric irritation, early morning wakening, hyperactivity, flu‐like illness </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0025" title="MurrayTJ . Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences1985;12(3):251-4. [PMID: 3902184]">Murray 1985</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>— </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation, nausea, anxiety, influenza‐like illness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0010" title="CohenRA , FisherM . Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology1989;46(6):676-80. [PMID: 2730380]">Cohen 1989</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine, pemoline in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No severe adverse reaction (did not lead to withdrawal)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline: palpitations, nausea, mood change, sleep disturbance, Amantadine: sleep disturbance, palpitations </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0019" title="GeislerMW , SliwinskiM , CoylePK , MasurDM , DoscherC , KruppLB . The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Archives of Neurology1996;53(2):185-8. [PMID: 8639070]KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dextroamphetamine</p> <p>in HIV‐positive men with fatigue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of 23 patients discontinued during the 2 weeks of DB, PC RCT</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overstimulation, heart palpitation, sleep deprivation, loss of appetite and/or weight, headache. The authors reported that adverse reactions generally were "transient, reversible, and well managed with dose reduction; no serious medical side effects were reported" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0041" title="WagnerGJ , RabkinR . Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2000;61(6):436-40. [PMID: 10901342]">Wagner 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamphetamine in advanced cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drop‐out rate in verum group compared to placebo group was statistically not significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant increase in pulse rate. Transient increase of dry mouth, insomnia, tremor, anorexia on days 6 and 8 (of 8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0002" title="AuretKA , SchugSA , BremnerAP , BulsaraM . A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. Journal of Pain and Symptom Management2009;37(4):613-21. [PMID: 18790598]">Auret 2009</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pemoline in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 of 46 dropped out because of adverse reaction; 25% of patients did not tolerate pemoline well according to the authors </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most common side effects were anorexia, irritability, "jitteriness" and insomnia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0042" title="WeinshenkerBG , PenmanM , BassB , EbersGC , RiceGP . A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology1992;42(8):1468-71. [PMID: 1641137]">Weinshenker 1992</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse reaction</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea, transient epigastric pain (nausea, headache and diarrhoea occurred with placebo)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0044" title="WingerchukDM , BenarrochEE , O'BrienPC , KeeganBM , LucchinettiCF , NoseworthyJH , et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology2005;64(7):1267-9. [PMID: 15824361]">Wingerchuk 2005</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate and pemoline in HIV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe side effects relatively uncommon; 5 withdrew (2 on methylphenidate, 2 on pemoline, 1 on placebo) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperactivity, jitteriness, dry mouth, rapid heart beat, difficulty sleeping, constipation, neuropathic pain (1 patient) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0005" title="BreitbartW , RosenfeldB , KaimM , Funesti-EschJ . A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine2001;161(3):411-20. [PMID: 11176767]">Breitbart 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate in advanced cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No severe adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most pts reported insomnia, anorexia, restlessness, behavioural change and vertigo. Numbers in placebo groups were similar </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0006" title="BrueraE , ValeroV , DriverL , ShenL , WilleyJ , ZhangT , et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2006;24(13):2073-8. [PMID: 16648508]">Bruera 2006</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Donepezil in advanced cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No severe adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most pts reported anorexia, nausea, restlessness, dizziness, behaviour change, vertigo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0007" title="BrueraE , El OstaB , ValeroV , DriverLC , PeiBL , ShenL , et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology2007;25(23):3475-81. [PMID: 17687152]">Bruera 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference in prevalence of adverse events reporting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most pts reported headache, insomnia, nausea, anxiety, dizziness, ataxia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0009" title="Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Canadian Journal of Neurological Sciences1987;14(3):273-8. [PMID: 2889518]">Canadian MSRG 1987</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paroxetine in end‐stage COPD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 of 12 pts dropped out because of adverse effects related to the drug</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Somnolence was reported by 5 pts, constipation, nausea, headache tremor were rated by 2 pts each </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0020" title="LacasseY , BeaudoinL , RousseauL , MaltaisF . Randomized trial of paroxetine in end-stage COPD. Monaldi Archives for Chest Disease2004;61(3):140-7. [PMID: 15679006]">Lacasse 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone for HIV‐positive pts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 of 46 pts discontinued because of adverse reactions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne, irritability, insomnia, headache, nasal congestion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0026" title="RabkinJG , WagnerGJ , RabkinR . A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Archives of General Psychiatry2000;57(2):141-7; discussion 155-6. [PMID: 10665616]">Rabkin 2000</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone and fluoxetine in HIV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine: diarrhoea, nausea, nonspecific discomfort<br/>Testosterone: sleepiness; all treatments: dry mouth, sleepiness, loose bowels </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0027" title="RabkinJG , WagnerGJ , McElhineyMC , RabkinR , LinSH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. Journal of Clinical Psychopharmacology2004;24(4):379-85. [PMID: 15232328]">Rabkin 2004</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil for HIV</p> <p>patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment‐emergent side effects were relatively uncommon</p> <p>CD4 cell count did not show either statistically or clinically significant changes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0029" title="RabkinJG , McElhineyMC , RabkinR , McGrathP . Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. Journal of Clinical Psychiatry2010;71(6):707-15. [PMID: 20492840]">Rabkin 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Armodafinil in HIV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Armodafinil was well tolerated, with few and transient adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The most common was headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0030" title="RabkinJG , McElhineyMC , RabkinR . Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics2011;52(4):328-36. [PMID: 21777715]">Rabkin 2011</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amantadine in post‐polio syndrome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> —</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insomnia was the commonest reported adverse reaction; dry mouth was noted by 1 patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0038" title="SteinDP , DambrosiaJM , DalakasMC . A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Annals of the New York Academy of Sciences1995;753:296-302. [PMID: 7611638]">Stein 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>L‐carnitine in</p> <p>end‐stage renal</p> <p>disease (ESRD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse event was believed by the investigators to be certainly or probably drug‐related </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flu syndrome, injection‐site reaction, pain, pharyngitis,</p> <p>headache and hypertension showed no difference in frequency between L‐carnitine and placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0004" title="BrassEP , AdlerS , SietsemaKE , HiattWR , OrlandoAM , AmatoA , et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. American Journal of Kidney Diseases2001;37(5):1018-28. [PMID: 11325685]">Brass 2001</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate in cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse effect</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some pts experienced nausea, vomiting, facial rash</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0014" title="EscalanteCP , MeyersC , ReubenJM , WangX , QiaoW , ManzulloE , et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer Journal (Sudbury, Mass.)2014;20(1):8-14. [PMID: 24445757]">Escalante 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluoxetine in cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A total of 16 adverse events were judged to be possibly due to the treatment and 6 to taking the placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergic reaction, cardiac arrhythmia, dyspnoea, headaches, dizziness, mood change, myalgia, fever, diarrhoea, abdominal pain </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0016" title="Jean-PierreP , MorrowGR , RoscoeJA , HecklerC , MohileS , JanelsinsM , et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer2010;116(14):3513-20. [PMID: 20564068]">Jean‐Pierre 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate in</p> <p>cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a significant difference in self reported toxicities (SED)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased levels of nervousness and appetite loss in the methylphenidate group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0023" title="MoraskaAR , SoodA , DakhilSR , SloanJA , BartonD , AthertonPJ , et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. Journal of Clinical Oncology2010;28(23):3673-9. [PMID: 20625123]">Moraska 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methylphenidate in</p> <p>cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No severe adverse reaction</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (31%) men who started receiving methylphenidate had to be discontinued from the study due to increased blood pressure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0032" title="RothAJ , NelsonC , RosenfeldB , ScherH , SlovinS , MorrisM , et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer2010;116(21):5102-10. [PMID: 20665492]">Roth 2010</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Medroxyprogesterone acetate (MPA) in cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea and vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0035" title="SimonsJP , AaronsonNK , VansteenkisteJF , ten VeldeGP , MullerMJ , DrenthBM , et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. Journal of Clinical Oncology1996;14(4):1077-84. [PMID: 8648360]">Simons 1996</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid and amantadine in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acetylsalicylic acid and amantadine are both well tolerated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The most common side effects of acetylsalicylic acid were nausea (n = 53) and transient epigastric pain (n = 51). The most common side effect of amantadine was also nausea (n = 51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0034" title="ShaygannejadV , JanghorbaniM , AshtariF , ZakeriH . Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurological Research2012;34(9):854-8. [PMID: 22979982]">Shaygannejad 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil in cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modafinil seemed to be well tolerated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most symptoms are nausea, vomiting, anxiety and headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0036" title="SpathisA , FifeK , BlackhallF , DuttonS , BahadoriR , WhartonR , et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of Clinical Oncology2014;32:1-8. [PMID: 24778393]">Spathis 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone in multiple sclerosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 adverse events were probably related to study treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain grade 3 and vomiting grade 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006788-bbs2-0045" title="YennurajalingamS , Frisbee-HumeS , PalmerJL , Delgado-GuayMO , BullJ , PhanAT , et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology2013;31(25):3076-82. [PMID: 23897970]">Yennurajalingam 2013</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>COPD = chronic obstructive pulmonary disease; DB = double‐blind; PC = placebo‐controlled; pts = participants RCT = randomised controlled trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of adverse reactions associated with fatigue treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/full#CD006788-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006788-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methylphenidate versus placebo in cancer</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 FACIT‐F score change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methylphenidate versus placebo in cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references#CD006788-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006788-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Modafinil versus placebo in multiple sclerosis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Fatigue score change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Modafinil versus placebo in multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references#CD006788-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006788-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pemoline versus placebo in multiple sclerosis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Fatigue score change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pemoline versus placebo in multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006788.pub3/references#CD006788-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006788.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006788-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006788-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006788-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD006788-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD006788-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD006788-note-0007">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006788\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006788\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006788\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006788\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006788\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006788.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006788.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006788.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006788.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006788.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714001573"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006788.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714001576"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006788.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d64059c63937a',t:'MTc0MDcxNDAwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 